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Abstract 
  
 
In 2012 prostate cancer contributed towards 8% (1.1 million cases) of all cancer incidences around 
the world. This type of cancer is prevalent in men between the ages of 65-79 years old, with 25% of 
all cases occurring in men younger than 65 years old. Treatments that are currently available for 
prostate cancer include surgery, hormone therapy, radiation therapy and chemotherapy. These 
treatment methods are either very invasive or have harsh side effects including diarrhoea, nausea, 
alter liver function, anaemia and fatigue.  
 
 
A wide range of anti-cancer drugs in use today have very poor physiochemical properties.  New 
knowledge in this area is required to develop an advanced drug delivery system that improves the 
properties of these drugs. An example is anti-androgenic drugs such as flutamide (FLT) used in 
hormonal therapy. The disadvantages to FLT are that it has low bioavailability in oral formulations, 
low aqueous solubility, compliance issues and rapid first pass metabolism.  
 
Recent advances in novel drug delivery have led to the formation of controlled release delivery 
systems using non-toxic polymeric microspheres. These polymeric microspheres encapsulate the 
active agent improving its bioavailability and compliance, reducing drug toxicity and side effects.  
The aim of this investigation was to develop a controlled release FLT delivery system in the form of 
poly (ε-caprolactone) (PCL) microspheres. The study was set out to evaluate the microspheres 
aesthetics, physicochemical properties and drug release behaviour. A central composite 
experimental design was employed to evaluate the effect of two process variables, (1) the polymer 
PCL at three different molecular weights (MW) 80kDa, 65kDa and 10kDa, (2) the surfactant 
(poly(vinyl alcohol) (PVA)  at two molecular weight ranges 13-23kDa and 30-70kDa. 
 
Preparing the organic phase consisted of 500mg of PCL and 50mg of FLT being completed dissolved 
in 10mL chloroform. The inorganic phase was formed by dissolving PVA in deionised water at a 0.5% 
weight/volume solution. The organic phase was added drop wise into the inorganic phase to create a 
1.30 oil/water ratio. The emulsion was homogenised at 5000rpm for 1 minute. The chloroform was 
rotary evaporated off, followed by centrifugation and being frozen for 24 hours. The scanning 
electron microscopy (SEM) analysis was carried out with a freeze dried sample of the microspheres. 
The percentage yield was calculated to see how the sample amount changed with two process 
variables. Using laser diffraction, the average diameter of microspheres was determined. The 
percentage encapsulation efficiency (%EE) was carried out by dissolving PCL-FLT microspheres in 
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chloroform and ethanol. The solution was centrifuged and the UV-absorbance was recorded at 
300nm. The in-vitro drug release was analysed via dissolution, PCL-FLT microspheres were 
suspended in a dialysis bag and stirred at 100rpm, in a phosphate buffer saline (PBS) solution.  
 
The SEM data suggested the PCL 80kDa/ PVA 30-70kDa formulation produced the smoothest and 
most uniform microspheres with the highest mean percentage encapsulation efficiency at 90.92% 
±1.08%. The micrographs showed that as the PCL MW increased from 10kDa to 80kDa the particle 
size increased from 5.5µm to 8.4µm. Regarding percentage yield the 80kDa/ PVA 13-23kDa FLT 
loaded formulations produced the most amount of product, averaging at 72.95% ±1.28%. However, 
after statistical analysis of %EE and product yield there was no significant difference in data between 
the two MW ranges of PVA (P>0.05). Dissolution results showed PCL 80kDa/ PVA 30-70kDa 
microspheres to have a maximal release of 80.23% over 16 days with an intial burst release of 
15.38% within the first 4 hours of dissolution. This suggested that encapsulted FLT microspheres can 
be administered less frequently (once every 2 weeks) at a lower dose (50mg), as the release rate 
(80.23%/ 16 days) of encapsulted FLT is slower than the half life of free FLT (8 hours). Overall the 
formulation that produced the most ideal microspheres regarding aesthetics, size, yield, 
encapsulation efficiency and dissolution was the PCL 80kDa/ PVA 30-70kDa formulation.  
 
Further studies that can be conducted include transition electron microscopy (TEM) analysis to 
evaluate the internal components of the PCL-FLT microsphere complex. A co-polymer such as 
poly(lactic-co-glycolic acid) (PLGA) can be incorparated along side PCL in order to further improve 
the encapsulation efficiency. Toxicity studies can also be carried out  involving prostate cancer cell 
lines (MTT Assay).               
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1.0. Introduction 
1.1. Background of Cancer   
Worldwide cancer is assessed as an enormous burden that is expected to increase due to the growth 
and aging of the population. Lifestyle behaviours also influence the risk of developing cancer, such as 
smoking, poor diet and physical inactivity. The focus of this study is prostate cancer which in 2012 
contributed to 8% of all cancer incidences at 1.1 million cases worldwide (Ferlay et al., 2012). 
 
The most common type of cancer found in men is prostate cancer, and makes up 26% of all male 
cancer diagnosis in the UK. In 2008, there were 34,335 men diagnosed with prostate cancer and 
9376 deaths as a result of the disease in England, Wales and Northern Ireland. In 2010 the figures 
increased to 9632 deaths. This type of cancer is predominant in men aged 65-79 years but, about 
25% of all cases occur in men younger than 65 years old (Cancer of the Prostate, 2011).   
 
1.2. About Prostate Cancer/ Current Therapies  
Prostate cancer is a disease of the prostate gland. The gland is approximately the same size as a 
walnut, present only in men in the pelvic region surrounding the urethra. The function of the 
prostate gland is to secrete the liquid portion of male semen, or seminal fluid which then carries the 
sperm made by the testes (seminal fluid is essential for reproduction) (Cramer et al., 2007; Kumar 
and Majumder, 1997).  
 
The size of the prostate gland can increases with age. This is not a result of cancer but is a condition 
known as benign prostatic hyperplasia (BPH). BPH does not usually form into cancer but an enlarged 
prostate gland can occasionally contain areas of cancerous cells. There are no specific symptoms for 
early prostate cancer.  
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The majority of prostate cancers initially form on the outer part of the prostate gland, away from the 
urethra. If the tumour is not large enough to put pressure on the urethra that transports urine out of 
the body, there may not be any symptoms that arise (Balistreri et al., 2014; Francini et al., 2014). 
 
As the benign or cancerous tumor grows there are a number of symptoms that may occur which 
include; 
 Difficulty passing urine, straining to pass it or stopping and starting  
 Rushing to the toilet (uncontrollable urination) 
 Increased frequency of passing urine (commonly at night) 
 A sense of not being able to fully empty the bladder   
 Blood when passing semen or urine (rare) 
 Pain during urination (rare symptom) 
 
Current Therapies 
The most common treatments for prostate cancer are surgery, hormone therapy, radiation therapy 
and chemotherapy (Balistreri et al., 2014; Francini et al., 2014). 
 
Surgery  
The type of surgery depends on; 
 The size of the cancer and whether it has spread 
 What the cells look like under the microscope (*Gleason score) 
 General health  
 
*Gleason score:  A Gleason score is given to prostate cancer based upon its microscopic appearance. 
Cancers with a higher Gleason score (5-7) or (8-10) are more aggressive and have a worse prognosis 
(Gleason and Mellinger, 1974).  
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A treatment option known as a total prostatectomy or radical prostatectomy which is the removal of 
the prostate gland may be recommended. This surgical procedure may often cure the prostate 
cancer if it has not spread beyond the prostate gland. Although this treatment can cure the cancer 
there may be some long term side effects such as erection problems which occurs in 70% of all 
patients. Another side effect is urine leakage, making it difficult to control the flow of urine. This is 
due to muscle damage within the bladder, and can be seen in 20% of all patients (Waxman et al., 
1997). 
 
Another option is an orchidectomy where the individual has both testicles removed. This procedure 
is carried out so the body cannot produce the hormone testosterone anymore. As prostate cancer is 
testosterone dependant, by removing the hormone producing gland it can shrink a locally advanced 
cancer or stop it from growing. Removing the testicles does not cure the cancer but can be used to 
control the growth of the cancer for months or even years. After surgery some men experience side 
effects such as hot flushes or/and erection problems. A less invasive method to prevent testosterone 
from being made is hormonal treatment (Paula et al., 2003).   
 
A surgery known as transurethral resection (TUR) can be recommended which involves the removal 
of the inner part of the prostate gland from around the urethra. This operation relieves symptoms 
such as being unable to pass urine. Having a TUR done is not a cure for prostate cancer but just a 
temporary symptom reliever (Marszalek et al., 2009). 
 
Radiotherapy  
External radiotherapy involves high doses of radiation which focuses on the prostate gland area. The 
treatment ensures the whole of the prostate gland is treated to a surround area of 1-2cm around 
the cancerous cells. This is to make sure that any cancerous cells that are close to the tumor are also 
treated (microscopic spread).  
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A patient can have external radiotherapy treatment if the cancer is between stage T1 and T3. This 
means the cancer is too small to be seen on scans or felt during an examination of the prostate 
gland, to the cancer covering the entire prostate gland and no further. If it has spread to different 
organs this treatment is likely to be ineffective. Usually treatment is given once a day, for 5 days 
each week. This course of administration normally lasts between 4-8 weeks (Greene et al., 2002).  
 
Internal radiotherapy in another option that involves that involves the inner part of the prostate 
gland. This is sometimes a curative method when the prostate cancer is completely contained within 
the prostate. This treatment is known as a brachytherapy and is normally recommended when the 
cancer is low risk. There are two types of brachytherapy, one being seed implantation low dose rate 
therapy (LDR) and the other being radioactive tube implantation - high dose rate therapy (HDR). The 
preferred choice with some patients is brachytherapy as they only need to attend the hospital once 
or twice.  
 
Brachytherapy may come with side effects post-surgery. The most common side effects are difficulty 
passing urine. Around 15% of men will not be able to voluntarily pass urine and a catheter is passed 
into the bladder for a few days (Cooperberg et al., 2010).  
 
Hormone Therapy  
The function of hormones is to control the growth and activity of normal cells. Prostate cancer cells 
depend on the testosterone to proliferate. Hormone treatment can be used to lower the amount of 
testosterone in the body, which reduces the risk of an early prostate cancer returning back after 
treatment or shrink an advanced tumor to slow its growth (Brawer, 2006). Depending on what stage 
the cancer has reached, hormone treatment can be considered as a monotherapy or in conjunction 
with chemotherapy. 
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Anti-androgenic drugs such as bicalutamide (Casodex), flutamide (Drogenil or Eulexin) or 
enzalutamide (Xtandi) can be prescribed. One of the most common hormonal treatments is 
flutamide. flutamide prevents testosterone initiating cellular division and growth which intern slows 
down the cancerous growth or shrinks an advanced tumor (Debruyna, 1996). It has been seen that 
between 1 and 10 patients suffer from the following side effects; 
 Changes in liver functionality (during treatment)  
 Mild case of feeling or being sick 
 Mild case of diarrhoea  
 Tiredness & fatigue 
 Emotional Distress  
 Difficulty sleeping 
 Reduced red blood cell count (anaemia)    
 
In conjunction with flutamide (FLT), the individual may be prescribed luteinising hormone (LH) 
blockers. This will prevent the pituitary gland from releasing the hormone that signals the testicles to 
produce testosterone (Horwich, 2006). Examples of LH blockers are: 
 Leuprorelin (Prostap) 
 Goserelin acetate (Zoladex) 
 Buserelin (Suprefact) 
 Triptorelin (Decapeptyl) 
 Histrelin (Vantas) 
 
These drugs are commonly administered intravenously, some being given every month, and others 
every 6 months (Horwich, 2006).   
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Chemotherapy   
Chemotherapy involves killing cancer cells using drugs. This method is only used if the cancer has 
spread to other body parts. In regards to prostate cancer the most common drug used in 
chemotherapy is Docetaxel (Taxotere). It may be used as a first line treatment alongside hormone 
therapy such as FLT if the prostate cancer has spread. Chemotherapy is quite an effective treatment 
over a long time period, but comes with a series of side effects depending on the drug combination. 
The most common side effects are a compromised immune system making the patient susceptible 
to infection, tiredness and fatigue and being prone to nose bleed and other bleeding issues 
(Beekman et al., 2005).    
 
1.3. Controlled Drug Delivery  
Current drug carrier systems, i.e. injectable implants, play a key role in controlled delivery of 
pharmacological drugs. Parenteral controlled release systems are of considerable importance for 
drugs as they require daily administration or have low bioavailability or high toxicity (Sandrap and 
Moes, 1993).  
 
When looking at the current administration of the anti-androgenic drug FLT (250mg) during the 
treatment it produces high levels of drug toxicity in the blood which can lead to long term side 
effects. The major side effect that continues after treatment has finished is loss of bone density and 
bone strength. It would be ideal if these drugs were made available in the blood at effective 
concentrations with reduced side effects for a longer duration. A way around the daily 
administration of drugs is the usage of polymeric carriers (nanospheres and microspheres) as 
controlled release systems (Blanco-Prieto et al., 1997).        
 
Producing biodegradable injectable delivery systems to transport drugs and to preserve the blood 
level in a desired therapeutic range for a long period of time improves compliance.   
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The design of the controlled release dosage form has other advantages over conventional dosage 
forms (Fell, 1996; Baumgartner et al., 2000; Moës, 1993): 
 Reduction in frequency of drug administration.  
 Reduction in drug level fluctuation.  
 Reduction in total drug used in comparison to conventional therapy. 
 Reduction in drug toxicity (Local/ Systemic). 
 Stabilisation of medical condition due to more uniform drug levels. 
 Economical to health care providers and patients.  
 
1.4. Biodegradable Polymers in Controlled Drug Delivery. 
In the pharmaceutical industry there are a variety of different polymers that are being used for 
controlled drug delivery. They can be synthetically manipulated for the use of many applications 
such as biofilms, nano-particles and micro-particles. Common polymers that are used include Poly-
D,L-lactide-co-glycolide (PLGA), Polylactic Acid (PLA) or poly(ε-caprolactone) (PCL). 
 
PLGA is known be a successfully used biodegradable microsystem for drug delivery as it undergoes 
hydrolysis in the body to produce biodegradable metabolite monomers such as lactic acid and 
glycolic acid. The body can effectively deal with these two monomers by metabolising them within 
the TCA cycle. PLGA is FDA approved for human use and has already been used to incorporate 
cancer therapeutic drugs such as Taxol, Paclitaxel and Docetaxel (Sahana et al., 2008).  
 
PLA is also a biodegradable and biocompatible material that undergoes scission into monomeric 
units of lactic acid as a natural intermediate in carbohydrate metabolism. PLA nano and 
microparticles are prepared using a technique known as solvent evaporation. This encapsulation 
method delivers the least amount of stress to the drug or proteins encapsulated. This polymer has 
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been used to encapsulate proteins such as haemoglobin, protein-c and neurotoxin-i (Fessi et al., 
1989). 
 
1.5. Poly(ε-Caprolactone)       
The synthetic polymer PCL (figure 1) has been of particular interest as it allows for a long sustained 
and possible controlled drug release rate (Chawla and Amiji, 2002). It has a very low glass transition 
temperature of approximately -60oC and has a melting point ranging between 59-64oC depending on 
chain length (molecular weight). PCL is ideal for controlled drug delivery in targeted cancer therapy, 
as it has a high permeability to a wide range of drugs and is non-toxic (Murthy, 1997). PCL is a 
biocompatible polymer with a very slow degradation rate, this makes it very ideal for long term 
delivery.  As it is a semi crystalline synthetic polymer and is extensively used in the pharmaceutical 
and biomedical fields as a biomaterial and for prolonged drug delivery systems targeting specific 
tissues within the body (Sinha et al., 2004). Out of the three polymers (PLGA, PLA and PCL), PCL is 
the most economically viable option being the cheapest to produce and has the least toxicity within 
the body. Also unlike PLA and PLG polymers PCL does not generate an acid environment, which 
could adversely affect the stability of a drug. Currently hormone altering drugs (FLT) have not been 
encapsulated within PCL microparticles. These types of drugs would be ideal candidates to be 
encapsulated within a PCL microsphere to initiate controlled release of the active agent. The 
polymer PCL undergoes hydrolysis of the ester linkages within the human body and has a slower 
degradation rate compared to the other lactide derived polymers (Kumari et al., 2010).     
 
 
 
 
Molecular weight: (114.14 g/mol)n 
 
Figure 1. Chemical structure of a free Poly(ε-Caprolactone) monomer unit (Created using Microsoft 
Word. 2010).  
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1.6. Chloroform (Solvent) 
The polymer PCL during the solvent evaporation process requires an appropriate solvent to dissolve 
the bioactive agent (Anti-cancer drug) and PCL polymer. Table 1 below shows a variety of the volatile 
solvents that are suitable and not suitable for dissolving PCL. Chloroform is an ideal solvent as it has 
the following characteristics; low boiling point (61oC), high volatility as well as being good at 
dissolving PCL (Maia et al., 2004). The bio-active agent FLT is also soluble in chloroform (Sigma 
Aldrich).  
 
During the solvent evaporation step in figure 4 the polymer and the solvent properties have to be 
taken into account to prevent any damage to the sample. The PCL has a boiling point melting ranging 
between 59oC and 64oC and has a polymer softening temperature of 35oC as listed by Sigma-Aldrich. 
The solvent Chloroform has a boiling point of 61oC which suggests for the microspheres to retain 
their rigidity during this process the rotary evaporator will be set at a constant controlled 
temperature of 30oC. 
           
Table 1. Solvents used for PCL polymer solubility (Chang et al., 1986).    
Poly-ε-caprolactone (PCL) Solvent Solubility  
(High Solubility) (Low Solubility) (Insoluble in) 
Chloroform Acetone Alcohol 
Dichloromethane 2-butanone Petroleum Ether 
Carbon tetrachloride Ethyl-acetate Di-ethyl ether 
Benzene Dimethylformamide  
Toluene Acetonitrile  
Cyclohexane   
2-nitropropane   
 
1.7. Flutamide 
The therapeutic drug involved in this investigation is flutamide (FLT) also known as Eulexin or 
Drogenil with an average molecular weight of 276.2 g/mol (Sortino et al., 2001). FLT shown in figure 
2 is prescribed as a hormonal therapeutic drug in combination with a luteinising hormone (LH) 
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blockers for treating prostate cancer (Martel et al., 2003). FLT is an anti-androgenic agent that is 
therapeutically effective for benign prostatic hypertrophy (BPH) and androgen dependent prostate 
cancer (Debruyna, 1996).  
 
Conventionally FLT 250mg (or 500mg) is orally administered three times daily which is in accordance 
to Cancer Research UK. The regular administration of FLT has a half-life of approximately 8 hours 
with 10 metabolites (Lemke and Williams, 2013). After oral administration FLT is absorbed from the 
gastrointestinal tract with a tmax of about 2 h. The two major metabolites after first pass metabolism 
are 2-hydroxyflutamide and the hydrolysis product 3-trifluromethyl-4-nitroalanine. Schulz and his 
team of researchers in 1988 saw that after a single 250mg dose of FLT the average maximum FLT 
plasma concentrations is 0.02 µg·ml−1 (n=3) (Schulz et al., 1988).  
 
The steroid hormones known as testosterone (androgens) have aids the proliferation of prostate 
tumors (Huggins and Hodges, 1941). Therapeutic agents such as anti-androgen are of great 
importance to society as they reduce androgen levels in target tissues. Two of the most common 
drugs currently being prescribed to treat prostate cancer are finasteride (Marketed by Merck & Co. 
as Proscar) and flutamide (Marketed by Schering-Plough as Eulexin).   
 
The drug FLT has a low bioavailability in oral formulations, which may be due to the poor wettability, 
low aqueous solubility (0.00566 mg/mL), low concentration at the absorption surface and rapid first 
pass hepatic metabolism after oral administration (Nari, 1989).  
 
It is necessary to develop an innovative formulation that mitigate solubility and dissolution 
sustaining a higher concentration of FLT at the absorption site, by overcoming first pass metabolism. 
The dosage characteristics of FLT (250mg three times daily) have indicated that it is a suitable 
candidate for a controlled-release delivery system, to improve patient’s compliance and reduce the 
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occurrence of side effects (Zuo et al., 2002). Despite these statistics, to our knowledge there has 
been no controlled release formulation of FLT that has been prepared until now (Elgindy et al., 
2010).  The bio-active agent FLT shown in figure 2 is soluble in the solvent chloroform which will be 
used primarily in this investigation (Sigma Aldrich).  
 
 
 
 
 
Molecular weight: (276.21 g/mol) 
Figure 2. Molecular structure of free flutamide (2-methyl-N-[4-nitro-3 
(trifluoromethyl)phenyl]propanamide) (Sortino et al., 2001).  
 
In this investigation FLT is being encapsulated with in a PCL polymer. To test for the presence of FLT 
throughout this study during various experiments the UV detection wavelength is 296nm, which 
detects the b-band of the benzene ring in the structure.  This wavelength is in accordance to Filip, M. 
and his team of researchers in 2007 regarding the “HPLC Monitoring of FLT Drug Used in the 
Prostate Cancer Treatment” (Filip et al., 2007). This wave length of 296 nm will be verified further in 
this current study.   
 
 
1.8. Surfactant 
 
During the formulation process a variety of excipients can be added to improve the stability of the 
drug during fabrication. The polymer-solvent-drug solution is emulsified by poly(vinyl alcohol) (PVA). 
The PVA shown in figure 3 is a white non-toxic biodegradable semi-crystalline polymer that can be 
used as an emulsifier or surfactant. It also has a very good aqueous solubility and is incorporated in 
the water phase of the preparation (Yang et al., 2001).    
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The reasoning for using a surfactant such as PVA during the production of polymeric microspheres is 
to reduce the amount of microsphere clumping producing a more uniform product (Arshady, 1991). 
Another reason for including a surfactant such as PVA is to stabilise the primary emulsion, resulting 
in more uniform distribution of microspheres (Yang et al., 2001). PVA will be tested as a surfactant in 
this investigation at two different molecular weight ranges (13-23kDa or 30-70kDa). 
 
Molecular weight: (44.05 g/mol)n 
Figure 3. Molecular structure of a Poly(Vinyl Alcohol) monomer unit (Rowe, 2012). 
 
1.9. Release Studies 
The fundamentals of controlled drug release is to change the pharmacokinetics and 
pharmacodynamics of a pharmacologically active agents by using advanced drug delivery systems, or 
altering the molecular structure and/ or physiological parameters occurring within a selected route 
of administration. During the controlled release of the polymer-drug microspheres they incorporate 
The controlled release delivery system encapsulates a drug within a polymeric microsphere the 
active agent is either dispersed or dissolved throughout the particle matrix (Neetika et al., 2012).  
 
The release kinetics of microspheres drug delivery systems suggest that if the concentration of drug 
encapsulated in the polymer core is constant (dependant on the drugs solubility in the solvent), the 
driving force of the drug release is constantly diffusing through the polymer membrane. The factors 
that influence the release rate are release area, thickness of the polymeric membrane, the implant 
form (microspheres) and drug solubility (Bourges et al., 2006). 
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Other dependant factors that can affect drug release are rate of diffusion of the drug from the 
delivery system, erosion of the polymer matric and biodegradation of the polymer. In cases where 
biodegradation and erosion of the polymer are slow, the release rate is strongly influenced by the 
drug diffusion pathway. The interaction between the drug-polymer, the pKA of the drug, the amount 
of drug loaded in the microsphere and the state of incorporation of the drug in the delivery system 
can influence the diffusion rate. The state of incorporation of the drug in the system and interaction 
between drug-polymer are important factors that affect the release profile (Maysinger et al., 2001). 
 
1.10. Research Aim 
In this study, it was aimed to develop a controlled release FLT delivery system in the form of PCL 
microspheres and investigate it for physicochemical properties and drug release behaviour. A central 
composite experimental design was employed to evaluate the effect of two process variables: i) The 
polymer poly (ε-caprolactone), three PCL molecular weights (80, 65 and 10kDa). ii) The surfactant 
(poly(vinyl alcohol), two PVA molecular weight ranges (13-23kDa and 30-70kDa). The objectives of 
the present study are to: 
 Prepare 12 formulations of PCL microspheres.  
o 6 empty PCL microspheres (using the two process variables mentioned above). 
o 6 FLT loaded PCL microspheres (using the two process variables mentioned above). 
 To determine the effects of different PVA molecular weight ranges via SEM analysis.  
 To investigate the effects of different PCL molecular weights on particle size. 
 To analyse the effects of different PCL molecular weights on encapsulation efficiency (Direct 
Method). 
 To analyse the effects of different PCL molecular weights on product yield.  
 To investigate the factors that influence different release profiles.  
 To determine the effect of different PCL molecular weights on the rate of drug release.      
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Taking all these objectives into account an overall conclusion can be deduced regarding which 
formulations are the most ideal for further development.   
 
2.0. Materials and Methodology 
2.1. Materials 
Poly-Ɛ-Caprolactone (PCL) (C6H10O2, 80,000 MW; CAS-No 24980-41-4)/ (C6H10O2, 65,000 MW)/ 
(C6H10O2, 10,000 MW), Flutamide (FLT) 2-methyl-N-[4-nitro-3 (trifluoromethyl) phenyl] propanamide 
(CAS-No. 13311-84-7), Chloroform (99%) (CHCl3, CAS-No. 67-66-3) and Ethanol (99%) (C2H6O, CAS-No. 
64-17-5) were all purchased from Sigma-Aldrich (Sigma-Aldrich inc, 3050 Spruce St., St. Louis, 
MO63103). Poly Vinyl Alcohol (13-23 and 30-70kDa) was purchased from Fluka Analytical. Phosphate 
Buffer Saline (Dulbecco A) was purchased from Oxoid Microbiology. Dialysis Membrane bags (Pur-A-
Lyzer™ Mega Dialysis Kit - 3-20ml - 3.5kDa MW - CAS-No. PURG35020-1KT) were purchased from 
Sigma-Aldrich (Sigma-Aldrich inc, 3050 Spruce St., St. Louis, MO63103). 
 
2.1.1. Equipment 
Homogeniser (IKA Labortechnik ULTRATURRAX TP 18/10 – 1000 – 10000 rpm), Rotovap Büchi 
Rotovapor re120, Varian 705 DS Dissolution Apparatus, Mastersizer (Malvern Mastersizer 3000 laser 
diffraction particle size analyser), Zeiss EVO50 SEM operated at (EHT) 10.00 kV and UV-
spectrophotometer, Perkin Elmer Lambda XLS (430nm), were all provided by the University of 
Wolverhampton. 
 
 
 
Sanjit S. Chaggar 1004138 Masters of Philosophy 
15 | P a g e  
 
2.2. Methods Development 
Prior to starting this laboratory investigation independent research was carried out to further 
develop the current protocols used in the Tang lab. 
 
The preparation process of microsphere particles is determined by the solubility of the drug and 
polymer (PCL) in various solvent systems. Two common systems used are;  
 
 Single emulsion solvent evaporation (Perez et al., 2000).  
 Double emulsion solvent evaporation (Dhanaraju et al., 2006; Cleek et al., 1997).  
 
The most common method of producing PCL microspheres is the single emulsion oil/ water (O/W) 
solvent evaporation method (figure 4), which will be used to carry out this investigation. The 
diagram in figure 4 summarises the production of drug loaded polymeric microspheres. There are 4 
distinctive steps involved (Li et al., 2008);  
 
1. Dissolving of the synthetic polymer in an ideal volatile organic solvent, then the addition of the 
active compound (active compound can be dissolved or simply dispersed in the organic phase).  
 
2. The emulsion of the organic phase is transferred in to an immiscible aqueous phase, forming the 
Oil/Water emulsion.  
 
3. The removal of the solvent from the dispersed phase, via solvent evaporation. Transforming the 
dispersed phase into solid particles.   
 
4. The harvesting and drying of the microspheres. 
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Figure 4. Main steps of the oil/water single emulsion-solvent evaporation method (Li et al., 2008).  
 
2.3. Investigation Outline 
PCL microspheres were formulated using a protocol that was previously used within Professor James 
Tang’s lab at the University of Wolverhampton. His past research suggested that microspheres made 
using PCL 80kDa produced the most ideal microspheres for the controlled drug release of FLT. 
However past investigation haven’t looked into using low a PCL molecular weight such as PCL 10kDa 
and different (Surfactant) PVA molecular weight ranges.   
  
This investigation analysed three different molecular weights of PCL microspheres (80kDa, 65kDa 
and 10kDa). Each microsphere formulation was created to also analyse the effects of two different 
PVA molecular weight ranges (13-23kDa and 30-70kDa). The microspheres formulations were 
prepared using a (single emulsion) solvent evaporation method. The investigation will include: 
 SEM analysis.   
 Percentage yield analysis (n=4). 
 Particle size analysis (n=5). 
 Percentage encapsulation efficiency analysis (n=3). 
 Drug release profile testing (n=3). 
This will suggest which formulation produces microspheres with optimal characteristics. 
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2.4. Preparing the Organic and Inorganic Phase 
500mg of PCL (80kDa, 65kDa and 10kDa) and 50mg of FLT were completely dissolved in 10mL 
Chloroform to make up the oil phase (organic phase). Then 1.25g of PVA (13-23kDa or 30-70kDa) 
was completely dissolved into 100mL deionised water, making up the water (inorganic) phase. This 
was then filtered using a 0.45µm filter into a 250mL conical flask and made up to 0.5% (wt/v) 
concentration with deionised water. This was then repeated with each MW of PCL (80kDa, 65kDa 
and 10kDa) and both low and medium MW of PVA surfactant (13-23kDa and 30-70kDa respectively). 
 When formulating the control microspheres (without FLT), during the preparation of the organic 
phase no FLT was added into the formulation.   
 
2.5. Preparing Microspheres  
2.5.1. Single Emulsion Drug Encapsulation 
The microspheres were formed using a 1:30 oil/water ratio (Pilaniya et al., 2011). 8mL of the organic 
phase (Oil) was added to 240mL of the inorganic phase (Water). This was then homogenised for 1 
minute at 5000 rpm using the IKA Labortechnik ULTRATURRAX TP 18/10.  
 
2.5.2. Solvent Evaporation/ Centrifugation and Freeze Drying 
The organic solvent (Chloroform) was then evaporated off at 30oC using Büchi Rotovapor re120 for 
20 - 30 minutes. The emulsion was then transferred to centrifuge tubes and centrifuged for 1 minute 
at 1000 x g, 1 minute at 3000 x g and 1 minute at 4500 x g, to turn the emulsion into a concentrated 
pellet of PCL-FLT microspheres. Upon centrifugation the samples were frozen for 24 hours    (-18oC) 
in preparation for the drying process. To remove the moisture and dry the sample it was then freeze 
dried using an Edwards EF4 Modulyo bench top freeze drier for 6 - 8 hours.  
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2.6. Particle Size Measurement  
All formulations were assessed using a particle size mastersizer (Malvern Mastersizer 3000 laser 
diffraction particle size analyser).  After the rotary evaporation step a 2ml sample of the emulsion 
was added drop wise to 100mL of deionised water until an obscuration rate of 15-30% was obtained. 
The sample was analysed for size distribution and particle size over five replicates. An absorption 
index of 0.001 and refractive index of 1.500 was used. The results were displayed as 10, 50 and 90% 
of the sample. After the initial analysis each sample was subjected to ultra-sonication to separate 
any large clumps of microspheres.      
 
2.7. Scanning Electron Microscopy  
Dry microspheres were placed onto an aluminium stub using double sided carbon tape and sputter 
coated with gold. They were placed into a Zeiss EVO50 scanning electron microscope, which is 
operated at (EHT) 10.00 kV. Various photomicrographs were taken at different magnifications for 
each sample.  
 
2.8. In-Vitro Drug Release 
In-vitro drug release of FLT from the drug loaded PCL microspheres was assesed using the dissolution 
tank method. The microspheres (20mg) were suspended in 20mL of phosphate buffer saline (PBS), 
pH 7.4, and placed into dialysis bags (Pur-A-Lyzer™ Mega Dialysis Kit - 3-20ml - 3,500kDa MW). The 
bags were tied to the paddle of the dissolution tank (Varian 705 DS Dissolution Apparatus) and 
dialysed against 900mL PBS, pH 7.4, as the dissolution medium. The dissolution system was 
maintained at 37 oC ± 0.5oC and was constantly stirred at 100 rpm. The total amount of drug released 
at set time intervals was determined by removing 5mL of the release media  and replenished with an 
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equal volume of fresh preheated (37oC) PBS. All samples were centrifuged at 4500 x g, and analysed 
ultraviolet absorbance at 300nm wavelength to detect the b-band of the benzene ring in FLT (Perkin 
Elmer Lambda XLS) using PBS as the blank (Elzoghby et al., 2013). 
 According to Philip, M and his team of researchers in 2007, they concluded that the b-band of 
benzene in FLT is  detected at 296nm of ultraviolet light. To confirm this, a FLT stock solution 
(0.05mg/ml ethanol) was scanned in a 1.4mL quartz cuvette using the Perkin Elmer Lambda XLS 
to produce an absorbance profile. The aborbance profile peaked at exactly 300nm on the 
spectrophotometer suggesting that the b-band of the benzene ring in FLT is detected at 300nm.   
 
2.9. Direct Encapsulation Efficiency 
Each sample (5mg) was completely dissolved in 0.5mL Chloroform and diluted with 10mL Ethanol. 
The samples were then centrifuged for three minutes (1 min at 1000 x g, 1 min at 3000 x g and 1 min 
at 4500 x g). The sample solutions were then transferred into a 25mL volumetric flask and diluted 
with more Ethanol, the absorbance of each sample was then analysed UV-spectrophotometrically 
(Perkin Elmer Lambda XLS) 300nm (Sivabalan et al., 2012). Each sample was read and the carried out 
in triplicate.  
 
To calculate the percentage efficiency will be converted from an arbitrary absorbance reading to a 
concentration using the line equation from the FLT calibration curve (dividing by the y= value). The 
formula (Chhater and Praveen, 2013):  
Percentage Encapsulation Efficiency =  
𝐴𝑐𝑡𝑢𝑎𝑙 𝐷𝑟𝑢𝑔 𝐶𝑜𝑛𝑡𝑒𝑛𝑡 (𝑚𝑔) 
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝐷𝑟𝑢𝑔 𝐶𝑜𝑛𝑡𝑒𝑛𝑡 (𝑚𝑔) 
 × 100 
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2.10. Indirect Encapsulation Efficiency 
The supernatant of each sample was collected after centrifugation during the production step 
(2.5.2.). Then 1mL of supernatant was extracted and re-centrifuged for 5 minutes at 5000 x g. 200µL 
of the supernatant was transferred into fresh Eppendorf tubes, into which 800µL of 95% ethanol was 
added to make up a 1mL solution. The samples were then thoroughly mixed and the absorbance’s 
read spectrophotometrically at 300nm (Perkin Elmer Lambda XLS). 
 Both the direct and indirect method can determine the percentage encapsulation of FLT. 
However the direct method is the most accurate technique to deduce the percentage 
encapsulation. The direct method breaks down the polymer capsule and detects the amount 
of FLT that is encapsulated within the microspheres to an accurate percentage. The only 
disadvantage to this method is that it will also take into account any unencapsulated FLT 
that is bound to the external surface of the microsphere. The indirect method detects 
encapsulation via calculating the amount of unencapsulated free FLT remaining in the 
supernatant after the rotary evaporation and centrifugation step. The encapsulated amount 
can be indirectly calculated from the absorbance readings (at 300nm).  This method 
indirectly calculates the amount of FLT that should be encapsulated but can only give an 
approximate value as opposed to the direct method, which is the most common method 
used and more accurate. 
 
2.11. Percentage Yield 
The percentage yield was calculated to determine the total amount of product obtained from the 
raw materials. The total percentage yield was calculated using the following formula (Prabu et al., 
2009): 
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Percentage Yield =  
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠 𝑜𝑏𝑡𝑎𝑖𝑛𝑒𝑑 (𝑑𝑟𝑦 𝑤𝑒𝑖𝑔ℎ𝑡) 
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑝𝑜𝑙𝑦𝑚𝑒𝑟+𝑑𝑟𝑢𝑔 
 × 100  
 The surfactant (PVA) is not included within the percentage yield formula because after the 
microspheres emulsion has been centrifuged and separated from the supernatant, followed by 
freezing and freeze drying the moisture has been removed. Therefore the amount of PVA 
remaining is in the dry sample is considered negligible.   
 
3.0. Results 
3.1. Scanning Electron Microscopy  
Figure 5 displays 12 comparative scanning electron microscope (SEM) micrographs (A-L), 6 of which 
show unencapsulated microspheres at 3 different poly (ɛ-caprolactone) (PCL) molecular weights 
(80kDa, 65kDa and 10kDa) and 2 different poly vinyl alcohol (PVA) molecular weight ranges (13-
23kDa and 30-70kDa). The remaining 6 micrographs show FLT encapsulated microsphere at the 
same formulation variables as the control batches (See Appendix 3.1.1. for detailed formulations). 
 
Image A illustrates fully formed smooth microspheres, with the majority being the same size 
showing an average diameter of 8.50µm diameter (n=10). It is apparent that there is low coagulation 
and all the chloroform (solvent) has been evaporated off efficiently, this is apparent from the 
spherical shape and the wrinkleless shell. Smaller 2.00µm (n=10) microspheres can be seen 
surrounding the larger microspheres (ratio: 1 Large : 2 small). When observing SEM image B there 
are two definitive sizes in this sample with little indication of uniformity. The majority of 
microspheres are showing an average diameter of 8.30µm (n=10). The micrograph also displays a 
large amount of small microspheres at an average 2.00µm in diameter (n=10) that have been formed 
surrounding the larger microspheres (ratio: 2 Large: 1 Small) (Scale Bars : 2.00µm).  
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Image C shows microspheres that are smooth and uniformly spherical at an average diameter of 
10.00µm (n=9), with is no indication of clumping or major wrinkling. There is an indication of one to 
two 2.00µm microspheres of PCL that can be seen in between the microspheres. SEM image D 
shows microspheres at an average diameter of 8.40µm (n=10) that are smooth and uniformly 
spherical, with is no indication of clumping or major wrinkling (Scale Bars : 2.00µm).  
 
Image E show fully formed microspheres at an average diameter of 8.30µm (n=3) with a minute 
amount of wrinkles on the surface of the spheres. Although fairly smooth, slight deformities are seen 
attached to the surface. These are clumps of PCL polymer about 1.00µm that haven’t fully formed 
and attached to the outer surface of the microspheres during the formulation process. SEM image F 
shows smoothly formed microspheres at an average diameter of 7.20µm (n=4) that have very little 
wrinkles and have a lot of uniformity as the spheres are nearly all the same size. Small PCL clumps 
seem to be visible, but unlike image E the free PCL polymer has not hindered the spherical shape of 
the microspheres (Scale Bars : 2.00µm).                
 
Image G shows fully formed microspheres at an average diameter of 9.60µm (n=3) that are quite 
smooth with a regular spherical shape and no clumping. The uneven layering seen on the 
background is due to both the structure of the carbon sticky, or scraped PCL polymer upon 
application. SEM image H show fully formed microspheres at an average diameter of 9.90µm (n=10) 
that have some wrinkles on the exterior. The majority of spheres are uniform in size with very little 
wrinkles, over all showing a fairly smooth exterior (Scale Bars: 2.00µm).    
Image I shows fully formed microspheres at an average diameter of 6.10µm (n=3) that are quite 
smooth with no clumping and minimal reference to surface wrinkles. SEM image J show fully formed 
microspheres at an average diameter of 5.90µm (n=4) that have some wrinkles on the exterior. The 
spheres are reasonably uniform but throughout the sample uniformity isn’t as apparent as sample I 
(Scale Bars : 2.00µm).     
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Image K illustrates fully formed smooth microspheres, with the majority being uniform in size. It is 
apparent that there is no coagulation between microspheres and structurally look spherical with a 
wrinkleless exterior. When observing SEM image L there are a variety of different sizes in this sample 
with minor indication of uniformity. The largest microspheres are at an average diameter of 5.5µm 
(n=10) and are surround by a variety of smaller microspheres between 1-2µm in diameter (n=10) 
(ratio: 1 Large : 2 smaller). The image also displays a large amount of small microspheres that have 
been formed surrounding the larger ones (Scale Bars : 2.00µm).   
 
When analysing the micrographs in figure 5, it is evident that as the molecular weight of PCL 
decreases from 80kDa to 10kDa, the diameter of microspheres on average decreases. The PCL 80kDa 
microspheres show an approximate 8.4µm diameter, reducing to 5.5µm when PCL 10kDa was 
utilised. Visually after comparing the empty and FLT encapsulated microspheres to each other, 
regarding size there is a small reduction in particle size after FLT was incorporated. 
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The PCL 80kDa formulation shown in figure 5 incorporated 2 molecular weights of PVA, both 
produced smooth microspheres. Figure 5 micrographs C and D incorporated a higher surfactant 
molecular weight range and displayed the most uniform microspheres amongst all the formulations. 
This visual analysis suggests that with a higher PVA molecular weight range (30-70kDa) increased 
uniformity of microspheres can be achieved. The effect of using PVA at a higher molecular weight 
range can be seen when comparing micrographs E, F to G, H and micrographs I, J to K, L.   
 
Overall figure 5 micrographs C and D displayed the most ideal microspheres for dissolution analysis. 
After evaluating their morphology it suggests the PVA 30-70kDa at 0.5% wt/v has stabilised the 
aqueous phase during formulation, creating very uniform and spherical microspheres as seen from 
the SEM micrograph.  
 
In figure 6 image A shows partially formed microspheres that are quite smooth but showing a large 
amount of clumping. Using the same experimental techniques throughout the formulation process, 
in this instance either not all the solvent has been evaporated or the drug did not fully encapsulate 
(Scale Bar : 2µm).  
 
 
 
 
 
 
 
Figure 6. A = SEM image of the FLT loaded PCL 10kDa - PVA 30-70kDa microspheres (4,000x mag) 
(See Appendix 3.1.1. for detailed formulations). 
 
A 
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3.2. Percentage Encapsulation Efficiency (Direct Method) 
Table 2 shows 3 different PCL polymer molecular weights (80kDa, 65kDa and 10kDa), which are then 
subdivided into 2 PVA surfactant molecular weight ranges (13-23kDa and 30-70kDa). Each individual 
formulation of FLT loaded microspheres was then tested using the direct encapsulation method. This 
analysis was carried out in triplicate to calculate the average percentage (Appendix 3.2.1.) The two-
tailed t-test p-value compared the percentage encapsulation efficiency of the PVA 13-23kDa 
formulations vs PVA 13-23kDa formulations. The definition of a statistical significance is a p-value 
that is <0.05 with a confidence interval of 95% or higher. A multiple comparison of column data was 
carried out using a Holm-Šídák’s test within a one-way ANOVA analysis (Using Graph Pad Prism 6) to 
establish whether there is a significant difference between the control and other sets of data (Table 
2). The Holm-Sidak’s multiple comparison test confirmed via p-values that there is a significant 
difference between the control and the other the sets of data.  
 
Table 2. A table displaying the direct percentage encapsulation efficiency of FLT in the test 
formulations (N=3) (Appendix 3.2.1.).    
 
(ns : P>0.05, * : P≤0.05, ** : P≤0.01, *** : P≤0.001 or **** : P≤0.0001) 
 
Figure 7 was created using the collected data displayed in table 2. Figure 7 proficiently illustrates 
that the over the three PCL molecular weights tested, 80kDa displayed the highest average %EE at 
90.12% ±0.56% and 90.92% ±1.08%. As the molecular weight of PCL reduced the encapsulation 
efficiency percentage also reduced.  
Direct Percentage Encapsulation Efficiency of FLT 
(Polymer)PCL MW 80kDa 65kDa 10kDa 
(Surfactant) PVA MW 13-23kDa 30-70kDa 13-23kDa 30-70kDa 13-23kDa 30-70kDa 
Average (%) 90.12 ±0.56 90.92 ±1.08 80.88 ±2.04 79.25 ±1.92 74.33 ±4.51 72.05 ±1.81 
(T-test) P value 0.3210 0.3701 0.4605 
Holm-Sidak's test (1) Control  **  **  
Holm-Sidak's test (2)  Control  ***  **** 
Sanjit S. Chaggar 1004138 Masters of Philosophy 
27 | P a g e  
 
When analysing the effect of the two PVA surfactant molecular weights, PCL 80kDa/ PVA 30-70kDa 
encapsulated 0.80% more FLT in comparison to PVA 13-23kDa. PCL 65kDa/ 13-23kDa encapsulated 
1.63% more FLT in comparison to PVA 30-70kDa. PCL 10kDa/ 13-23kDa encapsulated 2.25% more 
FLT in comparison to PVA 30-70kDa. The standard deviation was also calculated and plotted as 
standard error bars in figure 7. It suggests from the standard error that as the molecular weight of 
PCL reduced from 80kDa to 10kDa, the variance of percentage encapsulation efficiency in relation to 
the average increased.                 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. A graph showing the percentage encapsulation efficiency of FLT (using the direct method) 
in PCL microspheres (molecular weights : 80, 65 and 10kDa), each subdivided into two PVA 
molecular weights (molecular weights: 12-23 and 30-70kDa) (Appendix 3.2.1.).       
 
 
 
 
Average Percentage Encapsulation Efficiency of Flutamide (Direct Method)  
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3.3. Percentage Encapsulation Efficiency (Indirect Method) 
This analysis was carried out in triplicate to see how much free FLT was left encapsulated. Using 
these readings the theoretical percentage of encapsulated FLT was indirectly calculated.      
 
The indirect percentage encapsulation efficiency of FLT was calculated using the data shown in 
appendix 3.3.1. It was indirectly calculated that PCL 80kDa/ PVA 13-23kDa formulation gave an 
average percentage encapsulation of 92.20% ±0.22%, PCL 80kDa/ PVA 30-70kDa formulation gave an 
average percentage encapsulation of 90.52% ±1.44% (figure 8). The PCL 80kDa/ PVA 13-23kDa 
microspheres indirectly encapsulated 1.68% more FLT in comparison to PVA 30-70kDa. The standard 
deviation was also calculated and plotted as standard error bars in figure 8. It suggests from the 
standard error that formulation PVA 30-70kDa had a larger variance of %EE in relation to the 
average compared to the PVA 13-23kDa formulation.  
 
  
 
 
 
 
 
 
 
 
Figure 8. A graph showing the percentage encapsulation efficiency of FLT (using the indirect method) 
in PCL microspheres (molecular weight: 80kDa), which are subdivided into two PVA molecular 
weights ranges (molecular weights: 13-23 and 30-70kDa). 
 
H 
Average Percentage Encapsulation Efficiency of Flutamide (Indirect Method)  
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3.4. Percentage Yield 
Table 3 displays the percentage yield of both empty and FLT loaded microspheres. Each formulation 
has 3 different PCL polymer molecular weights (80, 65 and 10kDa), which are then subdivided into 2 
PVA surfactant molecular weight ranges (13-23 and 30-70kDa). When analysing the empty 
microsphere against the FLT loaded microsphere percentage yield, the percentage yield increases as 
drug is incorporated into the formulation.  
 
In table 3 the average percentage yield for formulations that produced “empty microspheres” was 
found to be between 64% - 71%. The highest percentage yield of microspheres were formulated 
using PCL 80kDa and PVA 13-23kDa, achieving 70.46% ±0.60% product. The lowest percentage yield 
of microspheres were formulated using PCL 10kDa and PVA 30-70kDa, displaying 63.92% ±2.02% 
product.  
 
The average percentage yield for formulations that produced “FLT Loaded Microspheres” was 
between 64% - 73%. The highest percentage yield of microspheres were formulated using PCL 80kDa 
and PVA 13-23kDa, with a yield of 72.95% ±1.28%. The lowest percentage yield were microspheres 
that were formulated using PCL 10kDa and PVA 30-70kDa, displaying  64.81% ±0.87% product. 
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Table 3. A table displaying the percentage yield of the test formulations (N=3) (Appendix 3.4.1.).   
Percentage Yield of Product  
Empty Microspheres 
(Polymer)PCL MW 80kDa 65kDa 10kDa 
(Surfactant) PVA MW 13-23kDa 30-70kDa 13-23kDa 30-70kDa 13-23kDa 30-70kDa 
Average (%) 70.46 ±0.60 70.11 ±1.61 69.71 ±4.37 69.39 ±1.05 64.94 ±1.42 63.92 ±2.02 
T-test (P value) 0.7258 0.9078 0.5128 
Holm-Sidak's test (1) Control  ns  ns  
Holm-Sidak's test (2)  Control  ns  ** 
FLT Loaded Microspheres  
(Polymer)PCL MW 80kDa 65kDa 10kDa 
(Surfactant) PVA MW 13-23kDa 30-70kDa 13-23kDa 30-70kDa 13-23kDa 30-70kDa 
Average (%) 72.95 ±1.28 71.98 ±0.04 70.62 ±0.34 69.64 ±4.33 65.60 ±1.09 64.81  ±0.87 
T-test (P value) 0.2585 0.6790 0.3846 
Holm-Sidak's test (3) Control  *  ***  
Holm-Sidak's test (4)  Control  ns  * 
∆ Average Percentage Yield (Average FLT Loaded Microspheres % - Average Empty Microspheres %) 
(Polymer)PCL MW 80kDa 65kDa 10kDa 
(Surfactant) PVA MW 13-23kDa 30-70kDa 13-23kDa 30-70kDa 13-23kDa 30-70kDa 
∆ Average Percentage 
Yield (%) 
+2.49 +1.87 +0.91 +0.25 +0.66 +0.82 
 
(ns : P>0.05, * : P≤0.05, ** : P≤0.01, *** : P≤0.001 or **** : P≤0.0001) 
 
3.5. Particle Size 
The 3 different PCL polymer molecular weights (80, 65 and 10kDa), which are then subdivided into 2 
PVA surfactant molecular weight ranges (13-23 and 30-70kDa) were assessed using a particle 
mastersizer (Malvern Mastersizer 3000 laser diffraction particle size analyser). The particle 
mastersizer is used to determine the size of microspheres that are present in the sample for both 
empty and drug loaded formulations. Figure 9 is a collaborative line graph of particle size that shows 
all the formulations, the highest peak in the graph displays what the average size of 90% of the 
sample was. It can be seen that as the PCL MW increases the peak shifts slightly to the right. This 
indicates that there is an increase in particle size as the PCL MW increases from 10kDa to 80kDa. The 
graph also indicates bimodal distribution, the highest peaks at 5.00-10.00µm (volume density 7-13%) 
and the shallow peaks at 0.01-0.20µm (volume density 1.00-3.00%). This shows that throughout all 
the formulations there were two groups of representable data. A small percentage of smaller 
micrsopheres and large percenatge of larger microspheres. The reason for the small percentage of 
smaller microspheres could be due to an excess amount PCL during the forulation stages. During the 
homogenisation process, excess PCL formed smaller PCL microspheres in emulsion. Another factor 
could be the homogenisation speed (5000rpm) being too high dispersing the emulsion more finely, 
creating smaller micropsheres.                   
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Figure 9. A collaborative line graph displaying the mastersizer data for all the microsphere formulations.  
 
 
 
 
 
: PCL 80kDa / PVA 13-23kDa (-FLT)  
: PCL 80kDa / PVA 13-23kDa (+FLT)  
: PCL 80kDa / PVA 30-70kDa (-FLT)  
: PCL 80kDa / PVA 30-70kDa (+FLT)  
: PCL 65kDa / PVA 13-23kDa (-FLT)  
: PCL 65kDa / PVA 13-23kDa (+FLT)  
: PCL 65kDa / PVA 30-70kDa (-FLT)  
: PCL 65kDa / PVA 30-70kDa (+FLT)  
: PCL 10kDa / PVA 13-23kDa (-FLT)  
: PCL 10kDa / PVA 13-23kDa (+FLT)  
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: PCL 10kDa / PVA 30-70kDa (-FLT)  
: PCL 10kDa / PVA 30-70kDa (+FLT)  
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Using the Malvern Mastersizer 3000 it provided quantitative data regarding the size of 
microspheres. All samples displayed  comparable microparticles ranging from 6.87µm to 11.50 µm 
(Dv90). When comparing the encapsulated drug formulations with the empty formulations, overall 
the morjority of formulations displayed a decrease in size when the drug was encaspsulated (Table 
4).  
 
Analysing 90% of each sample (Dv90), is displays that all the formulations shows a decrease in 
particle when comparing the “Empty” and “FLT Loaded” microspheres, excluding the PCL 65kDa/ 
PVA 30-70kDa and PCL 10kDa/ PVA 30-70kDa.              
 
Table 4. A table displaying the particle sizes of the test formulations (N=5). 
 
 
 
 
 
 
 
 
 
Particle Size (µm) 
Empty Microspheres 
(Polymer)PCL MW 80kDa 65kDa 10kDa 
(Surfactant) PVA MW 13-23kDa 30-70kDa 13-23kDa 30-70kDa 13-23kDa 30-70kDa 
(Dv90) µm 8.23 10.40 8.63 10.90 8.39 6.87 
FLT Loaded Microspheres  
(Polymer)PCL MW 80kDa 65kDa 10kDa 
(Surfactant) PVA MW 13-23kDa 30-70kDa 13-23kDa 30-70kDa 13-23kDa 30-70kDa 
(Dv90) µm 7.35 8.25 7.90 11.50 8.20 7.45 
∆ Particle Size (FLT Loaded Microspheres - Empty Microspheres) 
(Polymer)PCL MW 80kDa 65kDa 10kDa 
(Surfactant) PVA MW 13-23kDa 30-70kDa 13-23kDa 30-70kDa 13-23kDa 30-70kDa 
(Dv90) µm -0.88 -2.15 -0.73 +0.60 -0.19 +0.58 
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3.6. In-Vitro Release Studies 
The active substance FLT was analysed using a spectrophotometer to produce a calibration curve as 
seen in figure 10. The curve is an average of triplet readings for each dilution to improve reliability of 
data. Initially when analysing the stock solution (FLT : 0.05 mg/mL ethanol) the spectrophotometer 
displayed a digital absorbance spectrum that peaked at exactly 300nm wavelength.  The calibration 
graph in figure 10 produced a line equation (y=37.879x) that can be utilised to directly calculate the 
percentage FLT release at regular time intervals.  
 
Figure 10. Regression analysis of the calibration curve for Flutamide showed a linear relationship 
between the intensity of fluorescence and the concentration using a spectrophotometer at 300nm 
(N=3) (Appendix 3.6.1.). 
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The in-vitro release profile of the microsphere formulations are encapsulated using different PCL 
molecular weights (80kDa, 65kDa and 10kDa). These different formations of microspheres are then 
subdivided into two different PVA molecular weights ranges, (13-23kDa and 30-70kDa). 
 
This sigmoidal release profiles all have a common denominator, they display “first” order kinetics, 
suggesting, the drug release rate depends on its concentration. The release profiles in figure 11 
express 6 sigmoidal curves with 6 maximal parentage releases (Appendix 3.6.2.; 3.6.3. & 3.6.4.) : 
 
 PCL 80kDa-PVA 13-23kDa maximal release = 72.14% FLT. 
 PCL 80kDa-PVA 30-70kDa maximal release = 80.23% FLT. 
 
These maximal release readings were recorded after 16 days of dissolution until no more FLT was 
seen to be released. The supporting numerical data (Appendix 3.6.2.; 3.6.3. & 3.6.4) displays that the 
PCL 80kDa-PVA 13-23kDa formulation released about 19% of its active ingredient FLT within 4 hours 
of suspension. When analysing the PCL 80kDa-PVA 30-70kDa formulation data, it showed that it 
released about 15% of its encapsulated FLT within 4 hours of suspension. 
 
 PCL 65kDa-PVA 13-23kDa maximal release = 59.14% FLT release after 9 days. 
 PCL 65kDa-PVA 30-70kDa maximal release = 63.42% FLT release after 14 days. 
 
The supporting numerical data (Appendix 3.6.2.; 3.6.3. & 3.6.4) also suggested that the PCL 65kDa-
PVA 13-23kDa formulation released about 21% of its active ingredient FLT within 4 hours of 
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suspension. When analysing the PCL 65kDa-PVA 30-70kDa formulation data, it showed that it 
released about 12% of its encapsulated FLT within 4 hours of suspension. 
 
 PCL 10kDa-PVA 13-23kDa maximal release = 31.24% FLT release after 4 days. 
 PCL 10kDa-PVA 30-70kDa maximal release = 32.82% FLT release after 7 days. 
 
The supporting numerical data (Appendix 3.6.2.; 3.6.3. & 3.6.4) also suggested that the PCL 10kDa-
PVA 13-23kDa formulation released about 16% of its active ingredient FLT within 4 hours of 
suspension. When analysing the PCL 10kDa-PVA 30-70kDa formulation data, it showed that it 
released about 13% of its encapsulated FLT within 4 hours of suspension. 
 
After analysing the data in appendix 3.6.2.; 3.6.3. & 2.6.4 and figure 11 the results show that as the 
molecular weight of PCL increases, the rate of release slows down. This can be seen as the PCL 
80kDa formulation takes approximately 16 days to achieve maximal release. The PCL 10kDa released 
at a much faster rate with in only 4 days in comparison. In regards to the PVA molecular weight 
ranges it is significant that the PVA 30-70 molecular weight range causes an increase in maximal 
release throughout all the polymer molecular weights. It can also be determined from the release 
profiles in figure 11 that as the PCL molecular weight increases so does the maximal release 
percentage.         
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Figure 11. The in-vitro release profiles of all 6 FLT encapsulated microsphere samples. 
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4.0.  Discussion 
4.1. The Effects of PCL Molecular Weight on Particle Size. 
Analysing the data gathered from the scanning electron microscope micrographs shown in figure 5 
illustrate definitive features regarding aesthetics and size in relation to the different formulations. 
Figure 5 (A-L) demonstrate that as the PCL (polymer) decreased in molecular weight, visually there 
was also a small reduction in the microspheres diameter from 8.4µm to 5.5µm. The molecular 
weight of the polymer PCL is directly related to the chain length, as molecular weight decreases the 
chain length becomes shorter. The mechanical properties of the polymer are influenced by its 
molecular weight. To incorporate a polymer into the formulation that is strong and durable, the 
polymer has to have a molecular weight much larger than 10kDa for structural applications.  When 
formulations are relating to thin films or other special applications such as microparticles, low 
molecular weight polymer or oligomer occasionally is adequate (Sui, 2013).   
 
Sui’s research in 2013 stated that a polymer must be considerably larger than 10kDa to be used as 
polymeric microparticles. During this investigation, it was noted that formulations that incorporated 
PCL at 10kDa molecular weight (figure 5, (I-L)) displayed a lack of strength when being analysed by 
the SEM. The lack of stability can be seen as the electron beam was focused over a region of 
microspheres, within 15-30 seconds the microspheres began to disintegrate under the electron 
beam. This indicated that due to the low molecular weight of PCL 10kDa the microspheres do not 
hold a significant amount of strength and stability compared to the other formulations. These 
properties mean that PCL 10kDa has a very thin matrix, affecting its stability during the SEM analysis. 
This indicated that PCL 10kDa microspheres will degrade in a biological environment at a much 
faster rate compared to higher PCL molecular weights formulations, which is not ideal for controlled 
release.  
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4.2. Drug Overloading 
 
Figure 6, is an SEM image of microspheres using PCL 10kDa encapsulated with 50mg FLT. The image 
suggested that full encapsulation of FLT was unsuccessful.  This has caused a large amount of 
clumping with unencapsulated free FLT. The non-spherical flakes and connective strands inbetween 
the irregular clumps of PCL display the unencapsulted FLT. Small amounts of drug can be seen bound 
to the carbon backing as a thin film. The formation of small and fragile microspheres has led to them 
being unable to capacitate 50µg FLT in comparison to other formulations that incorporate higher PCL 
molecular weights. It was stated by Wise during his research in 2000 when studying the controlled 
release of poly(lactic-co-glycolic acid) (PLGA) a similar polymer to PCL that, 
“low polymer concentrations and low molecular weight polymers lead to lower viscosity mixtures 
and favour the formation of smaller microspheres” (Wise, 2000). Other supporting studies are by 
Ravi. S and his team in 2008 and Tiwari. S and his team in 2011 who discovered that while producing 
PLGA microspheres, as the polymer molecular weight was increased so did the microsphere size 
(Ravi et al., 2008; Tiwari and Verma, 2011).  
 
As a result of the data gained from the SEM micrograph in figure 6, a change in drug quantity was 
made when using PCL 10kDa. The drug quantity was amended from 50mg to 25mg, thus showing a 
significant improvement regarding microsphere formation and the amount of free drug left 
unencapsulted. A review paper by Metkar. V.B. and his team in 2014 states that “It was found that 
highest drug loading in microspheres may be achieved by incorporating the drug through the time of 
preparation but it may get affected by many other process variables like presence of additives, 
method of preparation, heat of polymerization, agitation intensity etc” (Metkar et al., 2014). In 
regards to the evidence found, by reducing the affecting variable (quantity of FLT during 
preparation) improved the microsphere yield using PCL 10kDa. Over loading microspheres of small 
size with active ingredients can reduce the efficiency of drug encapsulation, hence why a reduced 
amount of FLT (25 µg) was used for this particular formulation.      
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4.3. The Effect of Using PVA 0.5% wt/v 
Looking at the effect of the two different molecular weight ranges of PVA (13-23 and 30-70kDa) 
throughout the test formulations visually shows a significant change in morphology. In comparison 
to other studies by Ozlem Aydin in 2014, it was concluded that “spherical forms could be obtained 
with 1, 2, 4, and 6% wt/v PVA, but not with 0.5%” (Aydin et al., 2014). This investigation 
incorporated PVA 0.5% wt/v and spherical microspheres can be seen from the SEM micrographs in 
figure 5, therefore suggesting an alternative result.  
 
The SEM micrographs in figure 5 display that the surfactant has played a vital role in the stabilising of 
the primary emulsion. The result of incorporating PVA can be seen in Figure 5 - micrograph C-D, the 
microspheres are smooth and are very uniform in regards to size and distribution.  
 
4.4. Comparative Percentage Encapsulation Efficiency (Direct Method).  
The direct percentage encapsulation efficiency (%EE) of all the formulations shown in table 2 was 
found to be between 72.00% - 91.00%. When analysing the average %EE of formulations that 
incorporated the low molecular weight of PCL 10kDa, it was established that the microspheres could 
encapsulate 72.05% +/- 1.81% (PVA : 30-70kDa) and 74.33% +/- 4.51% (PVA : 13-23kDa) of FLT. In 
comparison to a study that investigated a drug delivery system of doxycycline-loaded 
polycaprolactone (PCL) microspheres in 2014 by Ozlem Aydin. The encapsulation of doxycycline 
using PCL 14kDa polymer produced microspheres that achieved an average %EE of 52.79% (Aydin et 
al., 2014). Although the PCL polymer molecular weights were not identical but still very similar (PCL 
10kDa against 14kDa), the data found from this investigation in comparison to Ozlem Aydin’s 
research shows ≈20% more drug can successfully be encapsulated into microspheres made with PCL 
10kDa. Although it can be seen that the PVA 13-23kDa formulations encapsulated more FLT into the 
microspheres compared to the PVA 30-70kDa formulations, after conducting a t-test a p-value of 
0.4605 signifies there is no significant difference between the two sets of data.    
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Table 2 displays formulations that incorporated PCL 65kDa, it was established that the microspheres 
could encapsulate 79.25% +/- 1.92% (PVA : 30-70kDa) and 80.88% +/- 2.04% (PVA : 13-23kDa) of FLT. 
Ozlem Aydin investigated the encapsulation of doxycycline using PCL 65kDa and it was established 
from the 2014 study that the produced microspheres had an %EE of 73.57% (Aydin et al., 2014). The 
data found from this investigation successfully encapsulated ≈7% more drug in PCL 65kDa 
microspheres when compared to Ozlem Aydin’s research. Although it can be seen that the PVA 13-
23kDa sample encapsulated more FLT into the microspheres compared to the PVA 30-70kDa 
formulation, after conducting a t-test a p-value of 0.3701 signifies there is no significant difference 
between the two sets of data. 
 
The final formulation that incorporated PCL 80kDa showed microspheres that could encapsulate 
90.92% +/- 1.08% (PVA : 30-70kDa) and 90.12% +/- 0.56% (PVA : 13-23kDa) of FLT. In comparison 
Liaqat Ali’s study from 2014 investigated the development of biodegradable PCL microspheres for 
controlled release of venlafaxine. It was established from the study that the produced PCL 80kDa 
microspheres achieved an %EE of 71.29% (Ali et al., 2014). The data found from this investigation 
successfully encapsulated ≈20% more drug in PCL 80kDa microspheres when compared to Liaqat 
Ali’s research. Although it can be seen that the PVA 30-70kDa sample encapsulated slightly more FLT 
into the microspheres compared to the PVA 13-23kDa formulation, after conducting a t-test a p-
value of 0.3210 signifies there is no significant difference between the two sets of data.   
              
Comparing the %EE from all the formulations proves that the larger PCL molecular weight 
formulations encapsulate more FLT in comparison to the 65kDa or 10kDa formulations. Statistically 
the difference in %EE in relation to the PCL molecular weight is very significant as P≤0.01..    
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 A benefit of improved encapsulation efficiency of PCL-FLT microspheres is that more of the active 
agent reaches the blood plasma to cause effect at the target site (testicles). This also means less FLT 
is needed in each dose, being more economically beneficial for the supplier. The controlled release 
microsphere system gives the benefit of reducing toxic concentrations of FLT in the blood plasma, 
reducing the likelihood of harsh side effects.       
 
4.5. The Effects of PCL Molecular Weight on Product Yield.  
Both “Empty” and “FLT Loaded Microspheres” decrease in product yield as the PCL molecular weight 
decreases. The reasoning for this is due to the reduction in microsphere diameter as the PCL 
molecular weight was reduced in formulation (PCL 80kDa  65kDa  10kDa). Another factor is that 
the likelihood of aggregation decreases as the mean diameter of the microspheres increases, 
because Brownian motion of smaller microspheres makes hydrophobic interactions more likely 
(Bang Laboratories. 2013). This theory shows that aggregation increases as the diameter of 
microspheres decrease, therefore making it harder to yield product as clumping is more likely to 
occur. Other than the PCL molecular weight, another viable reason for decreased production yield is 
a using a higher drug:polymer ratio (PCL 10kDa = 1:20) which causes a decreased diffusion rate of 
the solvent (chloroform) from concentrated solutions into initial emulsion (Youan et al., 2001).  
 
4.6. Factors Effecting Microsphere Size.  
The properties that are found in the aqueous phase are not the only factors that control 
microsphere size for further optimization of microspheres. The stirring speed has been found in 
other studies to affect particle size as it gives energy to disperse the organic phase more in water. A 
layer of foam on top of the solution had been produced due to the high stirring rate, the solution 
was left for 5 minutes to settle to reduce any excessive foam. Microsphere sizes were small in 
diameter due to the high stirring rate (5000 rpm) during the homogenisation process, as it results in 
Sanjit S. Chaggar 1004138 Masters of Philosophy 
42 | P a g e  
 
the formation of finer emulsions by breaking it up into smaller droplets (Aishwarya et al., 2008; 
Wang et al., 2008). In studies when the concentration of PVA was changed from 0.25% to 2.0% wt/v, 
microsphere sizes also decreased (Vivek et al., 2007). Therefore throughout this investigation the 
percentage concentration of PVA remained constant at 0.5% wt/v, to ultimately produce 
microspheres within a strict diameter range.   
 
Overall  seen from table 4 the data displays that using a higher PVA molecular weight range (30-
70kDa) a microsphere size increase can been achieved. A trend can be seen between the PCL MW 
and microsphere size, the higher PCL MW the larger the particle size. Jong-Keol Jeong and his team 
in 2003 when studying the release behaviour of PCL for drug release behaviour also discussed that 
using a higher PCL MW increases the particle size (Jeong et al., 2003).    
 
4.7. Factors Effecting Initial Burst Release and Maximal Release.  
The initial 4 hour dissolution period of formulation PCL 80kDa - PVA 13-23 (19 %DR)kDa and PCL 
65kDa - PVA 13-23kDa (21 %DR) presented the fastest burst release. A factor related to porosity is 
the previously mentioned initial burst effect within the first 4 hours of dissolution. This corresponds 
to a rapid initial release of the drug and is normally followed by a relatively-controlled linear release. 
This initial burst of FLT is attributed to leaching which occurs at the outer wall of the sphere as it 
becomes hydrated by the surrounding medium (LeCorre et al., 1994; Okada et al., 1994 and Ghaderi 
et al., 1996).   
 
According to the release profiles produced in this study, the largest initial burst of FLT in the first 4 
hours burst theoretically should have been in the formulations that incorporated PCL 10kDa. This is 
due to the porosity of the microsphere as it has a thinner matrix allowing medium to diffuse through 
the shell hydrating it.  However this did not occur, the reasoning for this anomaly may be due to the 
excess unencapsulated free FLT that can attach to the exterior surface of the microspheres. This 
Sanjit S. Chaggar 1004138 Masters of Philosophy 
43 | P a g e  
 
suggests that any surface bound FLT will induce a larger initial burst release, as shown for PCL 80kDa 
formulations. Supporting evidence from this study can be found in Figure 5, in micrographs A-H 
where is displays small surface flakes on the exterior surface of the microspheres which indicate un-
encapsulated free FLT, suggesting that 100% encapsulation may not have been achieved. 
 
Overall the formulations that incorporated PVA 30-70kDa proved to have a higher maximal 
controlled release but had a lower initial burst of FLT compared to PVA 13-23kDa formulations.  
Microspheres that were formed using PCL 80kDa displayed the highest deviation in max drug release 
percentage between the two PVA molecular weight ranges, the PCL 80kDa-PVA 30-70kDa 
formulation showed ≈8% increased percentage release. Previous studies have suggested that 
increasing “concentrations” of PVA decreased the initial burst of protein and the overall release 
rates (Jain et al., 2000). However external studies haven’t investigated two different PVA molecular 
weight ranges and compared there effects regarding release studies as shown in this investigation 
(Appendix: 3.6.2., 3.6.3. and 3.6.4.). 
 
4.8. The Effects of PCL Molecular Weight on Drug Release Rate. 
In this study the rate of release was dependant on the PCL molecular weight used. It was seen that 
the higher the PCL molecular weight the slower the rate of release overall.  As mentioned by 
Bezemer, J.M and his team of researches during their study into microspheres and protein delivery, 
“low-molecular-weight polymer resulted in porous, quickly releasing microspheres while the high-
molecular-weight formulation resulted in dense microspheres and produced a sigmoidal release 
profile” (Bezemer et al., 2000). 
 
The polymer molecular weight affects the polymers degradation and drug release rates. Review 
papers have stated that an increase in molecular weight decreases diffusivity and therefore drug 
release rate (LeCorre et al., 1994; Liggins and Burt, 2001). A mechanism for release of the active drug 
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is diffusion through water filled pores, formed as polymer degradation generates soluble monomers 
and oligomers that can diffuse out of the particle.  These smaller products are produced more 
readily during the degradation of lower molecular weight polymers such as PCL 10kDa (Blanco and 
Alonso, 1998).    
 
Another comparison can be made to this study by Jong-Keol Jeong and his team who also indicated 
that another factor mainly acted on drug release besides a particle size effect. The release behaviour 
seen is because the PCL molecular weight was high, the amorphous region will be wide open and 
form a coarse crystalline microstructure through which the drug will diffuse rapidly. Therefore it was 
determined by Jong and his team that the internal crystalline microstructure compared with particle 
size effect plays an important role in drug release (Jeong et al., 2003).  
 
5.0. Conclusions and Further Studies  
 
5.1. Conclusions 
This study concludes that we successfully prepared, developed and tested a controlled drug delivery 
systems consisting of Poly-(epsilon-caprolactone) encapsulating the prostate cancer chemotherapy 
drug FLT. The development stage allowed the microspheres formulation to be refined, taking into 
account the poly-(epsilon-caprolactone) molecular weight and the poly vinyl alcohol molecular 
weight range.   
 
Aesthetically from the SEM analysis it proves that a high PCL molecular weight (MW) (80kDa) at 0.5% 
wt/v PVA concentration and a high PVA MW range (30-70kDa) produce the most ideal drug delivery 
system. The microspheres are smooth, spherical in shape, uniform in size and well distributed. 
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Table 2 displays that when a lower PVA molceular weight range is used (13-23kDa) the percentage 
encapsultion of FLT is 1.60% higher on average compared to when PVA 30-70kDa is used. However 
after staistical analysis (t-test) the p-value suggests that there is no significant difference (p>0.05) 
between the PVA molecular weight ranges. The same sinerio can be seen in table 3 visually  when 
PVA 13-23kDa, it yields 1.00% on average more product in comparison to PVA 30-70kDa. Again after 
staistical analysis (t-test) the p-value suggests that there is no significant difference (P>0.05) 
between the PVA molecular weight ranges. The SEM micrographs and mastersizer samples have 
shown a small increment in particle size when the 80kDa PCL was used.  
 
Dissolution testing concluded that the higher PCL MW (80kDa) used the larger the maximal release, 
the slower the release rate of FLT and the higher the initial burst release.  The initial burst release 
data has suggested that further research will be needed to solidify the outcome in this study, for 
example an alternative formulation method to reduce external surface drug (double emulsion 
encapsulation). In regards to the affects of PVA the dissolution data confirms that a higher PVA MW 
range increases the maximal release through out all the formulations. When encapsulating within a 
low PCL MW polymer (10kDa) over encapsulation can occur causing clumping and a high percentage 
of unencapsulated free FLT. To overcome this problem, drug content was reduced to form uniform, 
spherical microspheres for further testing. The use of 0.5% wt/v of PVA has proven sucessful in this 
study and can be used to contradict other studies that have previously confirmed that 0.5% wt/v of 
PVA is insuficient to create spherical microspheres.  
       
A definitive single formulation can be selected from this study but further study is required. To 
conclude, the sample that has produced optimal data for a future controlled drug delivery system is 
the PCL 80kDa/ PVA 30-70kDa formulation. This formulation can be administered less frequently at a 
much lower dose (50mg), as the degredation rate (16 days) of PCL 80kDa is much slower than the 
Sanjit S. Chaggar 1004138 Masters of Philosophy 
46 | P a g e  
 
FLT half life (8 hours).  After further studies are carried out the synthesized delivery system may 
offer a successful and promising potential application for many diseases such as prostate cancer.  
 
5.2. Further Studies  
The conclusions have defined the success of this study; improvements are still needed to solidify the 
validity of the data collected. Looking at only the PCL 80kDa microspheres, further study will provide 
even more evidence to back up the integrity of the product.         
 
The first analysis to further the investigation will be transmission electron microscopy (TEM) 
analysis. This will show a cross sectional view of an individual microsphere and how FLT has been 
distributed throughout the microspheres core and also show the thickness of the matrix. Zhang and 
his team of researchers in 2003 successfully carried out TEM analysis on PLGA: PLLA polymer 
microspheres. Their TEM micrographs show a cross section of the microspheres allowing you see the 
enacapsulated Etanidazole (Zhang et al., 2003). 
 
Another development is looking into altering the formulation by encapsulating the active ingredient 
(Flutamide) within a co-polymer/diblock or triblock-polymer rather than a single PCL polymer as 
other studies show promising data. Cao and Shoichet while studying the “Delivering neuroactive 
molecules from biodegradable microspheres for application in central nervous system disorders”, 
displayed successful formulations when using a PCL-PLGA (50:50) diblock co-polymer (Cao and 
Shoichet, 1999).       
 
 A final development can be using in-vitro cytotoxicity testing such as MTT assay, this is a 
colorimetric test that analyses the drug delivery systems toxicity over a time period using cancer cell 
lines. (MTT assay protocol: Appendix 5.2.1.). This will indicate what dosage/dilution of PCL-FLT 
microspheres is therapeutic a specific time frame, causing cell apoptosis via the transcription factor 
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KLF9 which inhibits AKT activation and supresses tumor growth in prostate cancer patients (Shen et 
al., 2014).    
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7.0. Appendices 
 
Appendix : 3.1.1. 
Figure 5: Image (A) Formulation :  
 Batch : 2 
 Drug : No drug  
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 80kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 13-23kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Oil : Water Ratio = 1 : 30 
Figure 5: Image (B) Formulation : 
 Batch : 1 
 Drug : Flutamide - (50 µg)  
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 80kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 13-23kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Drug : Polymer Ratio = 1 : 10 
 Oil : Water Ratio = 1 : 30  
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Figure 5: Image (C) Formulation :  
 Batch : 4 
 Drug : No drug  
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 80kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 30-70kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Oil : Water Ratio = 1 : 30 
Figure 5: Image (D) Formulation : 
 Batch : 3 
 Drug : Flutamide - (50 µg)  
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 80kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 30-70kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Drug : Polymer Ratio = 1 : 10 
 Oil : Water Ratio = 1 : 30 
 
 
 
 
 
 
 
 
 
Sanjit S. Chaggar 1004138 Masters of Philosophy 
56 | P a g e  
 
Figure 5: Image (E) Formulation :  
 Batch : C10 
 Drug : No drug   
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 65kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 13-23kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Oil : Water Ratio = 1 : 30 
Figure 5: Image (F) Formulation :  
 Batch : C6 
 Drug : Flutamide - (50 µg)  
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 65kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 13-23kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Drug : Polymer Ratio = 1 : 10 
 Oil : Water Ratio = 1 : 30 
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Figure 5: Image (G) Formulation :  
 Batch : D10 
 Drug : No drug  
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 65kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 30-70kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Oil : Water Ratio = 1 : 30 
Figure 5: Image (H) Formulation :  
 Batch : D 
 Drug : Flutamide - (50 mg)  
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 65kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 30-70kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Drug : Polymer Ratio = 1 : 10 
 Oil : Water Ratio = 1 : 30 
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Figure 5: Image (I) Formulation :  
 Batch : A10 
 Drug : No Drug   
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 10kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 13-23kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Drug : Polymer Ratio = 1 : 10 
 Oil : Water Ratio = 1 : 30 
Figure 5: Image (J) Formulation :  
 Batch : A2 
 Drug : Flutamide - (25 mg) 
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 10kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 13-23kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Oil : Water Ratio = 1 : 30 
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Figure 5: Image (K) Formulation :  
 Batch : B10 
 Drug : No Drug 
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 10kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 30-70kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Drug : Polymer Ratio = 1 : 20 
 Oil : Water Ratio = 1 : 30 
Figure 5: Image (L) Formulation :  
 Batch : B2A 
 Drug : Flutamide - (25 mg) 
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 10kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 30-70kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Oil : Water Ratio = 1 : 30 
Figure 6: Image (A) Formulation :  
 Batch : B22 
 Drug : Flutamide - (50 mg)  
 Solvent : Chloroform - (10.0 mL) 
 Polymer : Poly-(epsilon-caprolactone) 10kDa - (500 mg) 
 Surfactant : Poly Vinyl Alcohol 30-70kDa - (1250 mg) 
 Homogenisation Speed: 5,000 rpm 
 Drug : Polymer Ratio = 1 : 20 
 Oil : Water Ratio = 1 : 3 
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Appendix :  3.2.1. 
 
Direct Percentage Encapsulation Efficiency Calculation Tables  
 
PCL 80kDa / PVA 13 - 23kDa  
 
 
Batch 1 Sample A Sample B Sample C 
 
Standard 
Curve of 
FLT: 
Abs 300nm 0.754 0.795 0.711 
y = 37.879x 
R² = 0.9983 
[FLT] cuvette 0.019905489 0.020987882 0.018770295 
Initial mg FLT 0.497637213 0.524697062 0.469257372 
Real mg 
FLT/mg FLT 
4.602362787 4.475302938 4.530742628 
Theoretical 
mg FLT/mg 
FLT 
5.1 5.0 5.0 Average 
%EE  90.24240758 89.50605877 90.61485256 90.1211063 
 
PCL 80kDa / PVA 30 - 70kDa  
 
 
Batch 3 Sample A Sample B Sample C 
 
Standard 
Curve of 
FLT: 
Abs 300nm 0.751 0.615 0.667 
y = 37.879x 
R² = 
0.9983 
[FLT] cuvette 0.019826289 0.016235909 0.017608701 
Initial mg FLT 0.495657224 0.405897727 0.440217535 
Real mg 
FLT/mg FLT 
4.404342776 4.694102273 4.359782465 
Theoretical 
mg FLT/mg 
FLT 
4.9 5.1 4.8 Average 
%EE  89.88454644 92.04122104 90.82880136 90.91818961 
 
PCL 65kDa / PVA 13 - 23kDa  
 
 
Batch C6 Sample A Sample B Sample C 
 
Standard 
Curve of 
FLT: 
Abs 300nm 1.305 1.456 1.548 
y = 37.879x 
R² = 
0.9983 
[FLT] cuvette 0.034451807 0.038438185 0.040866971 
Initial mg FLT 0.861295177 0.960954619 1.021674279 
Real mg 
FLT/mg FLT 
4.138704823 4.139045381 3.778325721 
Theoretical 
mg FLT/mg 
FLT 
5.0 5.1 4.8 Average 
%EE  82.77409647 81.15775258 78.7151192 80.88232275 
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PCL 65kDa / PVA 30 - 70kDa  
 
 
Batch D Sample A Sample B Sample C 
 
Standard 
Curve of 
FLT: 
Abs 300nm 1.566 1.515 1.651 
y = 37.879x 
R² = 0.9983 
[FLT] cuvette 0.041342168 0.039995776 0.043586156 
Initial mg FLT 1.033554212 0.999894401 1.089653898 
Real mg 
FLT/mg FLT 3.966445788 4.300105599 3.710346102 
Theoretical 
mg FLT/mg 
FLT 
5.0 5.3 4.8 Average 
%EE  79.32891576 81.13406791 77.29887713 79.2539536 
 
PCL 10kDa / PVA 13 - 23kDa  
 
 
Batch A2 Sample A Sample B Sample C 
 
Standard 
Curve of 
FLT: 
Abs 300nm 1.921 2.254 1.515 
y = 37.879x 
R² = 0.9983 
[FLT] cuvette 0.050714116 0.059505267 0.039995776 
Initial mg FLT 1.2678529 1.487631669 0.999894401 
Real mg 
FLT/mg FLT 
3.5321471 3.512368331 3.800105599 
Theoretical 
mg FLT/mg 
FLT 
4.8 5.0 4.8 Average 
%EE  73.58639792 70.24736661 79.16886665 74.3342104 
 
PCL 10kDa / PVA 30 - 70kDa  
 
 
Batch B2A Sample A Sample B Sample C 
 
Standard 
Curve of 
FLT: 
Abs 300nm 2.258 2.151 1.985 
y = 37.879x 
R² = 
0.9983 
[FLT] cuvette 0.059610866 0.056786082 0.052403707 
Initial mg FLT 1.490271654 1.41965205 1.310092663 
Real mg 
FLT/mg FLT 
3.509728346 3.68034795 3.689907337 
Theoretical 
mg FLT/mg 
FLT 
5.0 5.1 5.0 Average 
%EE  70.19456691 72.1636853 73.79814673 72.05213298 
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Appendix : 3.3.1.  
 
Indirect Percentage Encapsulation Efficiency Calculation Tables  
PCL 80kDa / PVA 13 - 23kDa  
 
 
Batch 1 Sample A Sample B Sample C 
 
Standard 
Curve of 
FLT: 
Abs 300nm 0.363 0.383 0.38 
y = 37.879x 
R² = 0.9983 
[FLT] cuvette 0.009583146 0.010111143 0.010031944 
Initial mg FLT 3.833258534 4.044457351 4.012777528 
Real mg 
FLT/mg FLT 46.66674147 46.45554265 46.48722247 
Theoretical 
mg FLT/mg 
FLT 50.5 50.5 50.5 
Average 
%EE  92.40938904 91.99117356 92.05390588 92.2002813 
 
PCL 80kDa / PVA 30 - 70kDa  
 
 
Batch 3 Sample A Sample B Sample C 
 
Standard 
Curve of 
FLT: 
Abs 300nm 0.442 0.460 0.333 
y = 37.879x 
R² = 
0.9983 
[FLT] cuvette 0.011662885 0.012137844 0.008786743 
Initial mg FLT 4.665153834 4.855137474 3.514697346 
Real mg 
FLT/mg FLT 45.53484617 45.34486253 46.68530265 
Theoretical 
mg FLT/mg 
FLT 50.2 50.2 50.2 
Average 
%EE  90.70686487 90.32841141 92.99861087 90.51763814 
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Appendix : 3.4.1. 
 
Percentage Yield Calculation Tables 
80kDa With FLT (PVA 13 -23kDa) 
Sample 1 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6738 14.7701 
2 14.7149 14.8103 
3 14.6917 14.7938 
4 14.7541 14.8625 
Total 58.8345 59.2367 
   
Dry Weight - Test Tube (g) 0.4022   
  
  
  
Mass of PCL in Preparation (g) 0.5060 
Mass of FLT in Preparation (g) 0.0553 
Total (PCL +/- FLT) (g) 0.5613  
  
Percentage Yield (%) 71.66   
 
80kDa With FLT (PVA 13 -23kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6800 14.8021 
2 14.6269 14.7591 
3 14.7694 14.8152 
4 14.7510 14.8599 
Total 58.9158 59.3202 
    
Dry Weight - Test Tube (g) 0.4044   
  
  
  
Mass of PCL in Preparation (g) 0.5033 
Mass of FLT in Preparation (g) 0.0508 
Total (PCL +/- FLT) (g) 0.5541 
  
Percentage Yield (%) 72.98   
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80kDa With FLT (PVA 13 -23kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6800 14.8021 
2 14.6269 14.7591 
3 14.7694 14.8152 
4 14.7510 14.8599 
Total  58.8273 59.2363 
    
Dry Weight - Test Tube (g) 0.4090   
  
  
  
Mass of PCL in Preparation (g) 0.4999 
Mass of FLT in Preparation (g) 0.0512 
Total (PCL +/- FLT) (g) 0.5511 
  
Percentage Yield (%) 74.22   
Average Percentage Yield (%)  
(3 Sample)  
72.95 
 
80kDa Without FLT (PVA 13 -23kDa) 
Sample 1 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.7159 14.8172 
2 14.7558 14.8267 
3 14.7268 14.8181 
4 14.7545 14.8460 
Total 58.9530 59.3080 
   
Dry Weight - Test Tube (g) 0.3550   
  
  
  
Mass of PCL in Preparation (g) 0.5006 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5006 
  
Percentage Yield (%) 70.91   
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80kDa Without FLT (PVA 13 -23kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6789 14.7872 
2 14.6691 14.7131 
3 14.7852 14.8096 
4 14.8453 15.0190 
Total 58.9785 59.3289 
   
Dry Weight - Test Tube (g) 0.3504   
  
  
  
Mass of PCL in Preparation (g) 0.5022 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5022 
  
Percentage Yield (%) 69.77   
 
80kDa Without FLT (PVA 13 -23kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.4599 14.6587 
2 14.6641 14.6615 
3 14.6573 14.7124 
4 14.6854 14.7876 
Total  58.4667 58.8202 
    
Dry Weight - Test Tube (g) 0.3535   
  
  
  
Mass of PCL in Preparation (g) 0.5001 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5001 
  
Percentage Yield (%) 70.69   
Average Percentage Yield (%)  
(3 Sample)  
70.46 
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80kDa With FLT (PVA 30 -70kDa) 
Sample 1 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.7761 14.8834 
2 14.7521 14.8545 
3 14.8448 14.9442 
4 14.8021 14.8942 
Total 59.1751 59.5763 
   
Dry Weight - Test Tube (g) 0.4012   
  
  
  
Mass of PCL in Preparation (g) 0.5078 
Mass of FLT in Preparation (g) 0.0492 
Total (PCL +/- FLT) (g) 0.5570 
  
Percentage Yield (%) 72.03   
 
80kDa With FLT (PVA 30 -70kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.7130 14.8021 
2 14.3201 14.4052 
3 14.3470 14.4689 
4 14.2594 14.3671 
Total 57.6395 58.0433 
   
Dry Weight - Test Tube (g) 0.4038   
  
  
  
Mass of PCL in Preparation (g) 0.5098 
Mass of FLT in Preparation (g) 0.0514 
Total (PCL +/- FLT) (g) 0.5612 
  
Percentage Yield (%) 71.95   
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80kDa With FLT (PVA 30 - 70kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6525 14.7639 
2 14.6202 14.7376 
3 14.5776 14.6578 
4 14.7010 14.7944 
Total  58.5513 58.9537 
    
Dry Weight - Test Tube (g) 0.4024   
  
  
  
Mass of PCL in Preparation (g) 0.5090 
Mass of FLT in Preparation (g) 0.0502 
Total (PCL +/- FLT) (g) 0.5592 
  
Percentage Yield (%) 71.96   
Average Percentage Yield (%)  
(3 Sample)  
71.98 
 
80kDa Without FLT (PVA 30 -70kDa) 
Sample 1 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.7053 14.7958 
2 14.7105 14.8115 
3 14.6977 14.7804 
4 14.7227 14.8109 
Total 58.8362 59.1986 
   
Dry Weight - Test Tube (g) 0.3624   
  
  
  
Mass of PCL in Preparation (g) 0.5059 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5059 
 
Percentage Yield (%) 71.63   
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80kDa Without FLT (PVA 30 -70kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6385 14.6813 
2 14.6824 14.7942 
3 14.7076 14.7983 
4 14.7208 14.8280 
Total 58.7493 59.1018 
   
Dry Weight - Test Tube (g) 0.3525   
  
  
  
Mass of PCL in Preparation (g) 0.5152 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5152 
 
Percentage Yield (%) 68.42   
 
80kDa Without FLT (PVA 30 - 70kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6671 14.7766 
2 14.7189 14.8154 
3 14.7113 14.8022 
4 14.7217 14.7784 
Total  58.8190 59.1726 
    
Dry Weight - Test Tube (g) 0.3536   
  
  
  
Mass of PCL in Preparation (g) 0.5031 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5031 
  
Percentage Yield (%) 70.28   
Average Percentage Yield (%)           
(3 Sample)  
70.11 
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65kDa With FLT (PVA 13 -23kDa) 
Sample 1 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.7541 14.8650 
2 14.6941 14.7805 
3 14.7267 14.8247 
4 14.7340 14.8290 
Total 58.9089 59.2992 
   
Dry Weight - Test Tube (g) 0.3903   
  
  
  
Mass of PCL in Preparation (g) 0.5006 
Mass of FLT in Preparation (g) 0.0505 
Total (PCL +/- FLT) (g) 0.5511 
 
Percentage Yield (%) 70.82   
 
65kDa With FLT (PVA 13 -23kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6821 14.7914 
2 14.7403 14.8338 
3 14.7221 14.8201 
4 14.7260 14.8151 
Total 58.8705 59.2604 
   
Dry Weight - Test Tube (g) 0.3899   
  
  
  
Mass of PCL in Preparation (g) 0.5052 
Mass of FLT in Preparation (g) 0.0500 
Total (PCL +/- FLT) (g) 0.5552 
 
Percentage Yield (%) 70.22   
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65kDa With FLT (PVA 13 - 23kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6754 14.7849 
2 14.7660 14.8719 
3 14.7658 14.8681 
4 14.6549 14.7267 
Total  58.8621 59.2516 
    
Dry Weight - Test Tube (g) 0.3895   
  
  
  
Mass of PCL in Preparation (g) 0.5000 
Mass of FLT in Preparation (g) 0.0501 
Total (PCL +/- FLT) (g) 0.5501 
  
Percentage Yield (%) 70.81   
Average Percentage Yield (%)           
(3 Sample)  
70.62 
 
65kDa Without FLT (PVA 13 -23kDa) 
Sample 1 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.7594 14.8780 
2 14.7341 14.8141 
3 14.7194 14.8047 
4 14.6945 14.7730 
Total 58.9074 59.2698 
   
Dry Weight - Test Tube (g) 0.3624   
  
  
  
Mass of PCL in Preparation (g) 0.5005 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5005 
 
Percentage Yield (%) 72.41   
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65kDa Without FLT (PVA 13 -23kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.7885 14.8848 
2 14.6666 14.7500 
3 14.7980 14.8908 
4 14.6642 14.7531 
Total 58.9173 59.2787 
 
Dry Weight - Test Tube (g) 0.3614   
  
  
  
Mass of PCL in Preparation (g) 0.5016 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5016 
 
Percentage Yield (%) 72.05   
 
65kDa Without FLT (PVA 13 - 23kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6200 14.7010 
2 14.7625 14.8625 
3 14.6584 14.7534 
4 14.6480 14.6967 
Total  58.6889 59.0136 
    
Dry Weight - Test Tube (g) 0.3247   
  
  
  
Mass of PCL in Preparation (g) 0.5021 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5021 
  
Percentage Yield (%) 64.67   
Average Percentage Yield (%)           
(3 Sample)  
69.71 
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65kDa With FLT (PVA 30 - 70kDa) 
Sample 1  
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6842 14.7684 
2 14.6648 14.7701 
3 14.6381 14.7707 
4 14.7864 14.8669 
Total 58.7735 59.1761 
 
Dry Weight - Test Tube (g) 0.4026   
  
  
  
Mass of PCL in Preparation (g) 0.5011 
Mass of FLT in Preparation (g) 0.0504 
Total (PCL +/- FLT) (g) 0.5515 
  
Percentage Yield (%) 73.00   
 
65kDa With FLT (PVA 30 - 70kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6314 14.7404 
2 14.7168 14.8214 
3 14.7237 14.8119 
4 14.7660 14.8226 
Total 58.8379 59.1963 
 
Dry Weight - Test Tube (g) 0.3584   
  
  
  
Mass of PCL in Preparation (g) 0.5034 
Mass of FLT in Preparation (g) 0.0501 
Total (PCL +/- FLT) (g) 0.5535 
 
Percentage Yield (%) 64.75   
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65kDa With FLT (PVA 30 - 70kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6754 14.7834 
2 14.7660 14.8912 
3 14.7658 14.8566 
4 14.6549 14.7234 
Total  58.8621 59.2546 
    
Dry Weight - Test Tube (g) 0.3925   
  
  
  
Mass of PCL in Preparation (g) 0.5015 
Mass of FLT in Preparation (g) 0.0500 
Total (PCL +/- FLT) (g) 0.5515 
  
Percentage Yield (%) 71.17   
Average Percentage Yield (%)           
(3 Sample)  
69.64 
 
 
 
 
 
 
 
 
65kDa Without FLT (PVA 30 - 70kDa) 
Sample 1  
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6459 14.7305 
2 14.6113 14.7186 
3 14.6897 14.7535 
4 14.7945 14.8890 
Total 58.7414 59.0916 
 
Dry Weight - Test Tube (g) 0.3502   
  
  
  
Mass of PCL in Preparation (g) 0.5005 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5005 
 
Percentage Yield (%) 69.97   
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65kDa Without FLT (PVA 30 - 70kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.7684 14.8761 
2 14.7689 14.8360 
3 14.6289 14.7184 
4 14.7632 14.8409 
Total 58.9294 59.2714 
 
Dry Weight - Test Tube (g) 0.3420   
  
  
  
Mass of PCL in Preparation (g) 0.5016 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5016 
 
Percentage Yield (%) 68.18   
65kDa Without FLT (PVA 30 - 70kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6349 14.7016 
2 14.7713 14.8664 
3 14.7690 14.8462 
4 14.7541 14.8666 
Total  58.9293 59.2808 
    
Dry Weight - Test Tube (g) 0.3515   
  
  
  
Mass of PCL in Preparation (g) 0.5020 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5020 
  
Percentage Yield (%) 70.02   
Average Percentage Yield (%)           
(3 Sample)  
69.39 
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10kDa With FLT (PVA 13 - 23kDa) 
Sample 1 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.7613 14.8266 
2 14.6725 14.7625 
3 14.6984 14.8111 
4 14.7364 14.8180 
Total 58.8686 59.2182 
 
Dry Weight - Test Tube (g) 0.3496   
  
  
  
Mass of PCL in Preparation (g) 0.5009 
Mass of FLT in Preparation (g) 0.0249 
Total (PCL +/- FLT) (g) 0.5258 
 
Percentage Yield (%) 66.49   
10kDa With FLT (PVA 13 - 23kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6211 14.7116 
2 14.7391 14.8138 
3 14.7466 14.8228 
4 14.6347 14.7349 
Total 58.7415 59.0831 
 
Dry Weight - Test Tube (g) 0.3416   
  
  
  
Mass of PCL in Preparation (g) 0.5052 
Mass of FLT in Preparation (g) 0.0254 
Total (PCL +/- FLT) (g) 0.5306 
 
Percentage Yield (%) 64.38   
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10kDa With FLT (PVA 13 - 23kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6335 14.7354 
2 14.7157 14.8119 
3 14.7100 14.7656 
4 14.7693 14.8617 
Total  58.8285 59.1746 
    
Dry Weight - Test Tube (g) 0.3461   
  
  
  
Mass of PCL in Preparation (g) 0.5000 
Mass of FLT in Preparation (g) 0.0250 
Total (PCL +/- FLT) (g) 0.5250 
  
Percentage Yield (%) 65.92   
Average Percentage Yield (%)           
(3 Sample)  
65.60 
10kDa Without FLT (PVA 13 - 23kDa) 
Sample 1 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.8018 14.8670 
2 14.6845 14.7762 
3 14.6448 14.7214 
4 14.6369 14.7222 
Total 58.7680 59.0868 
 
Dry Weight - Test Tube (g) 0.3188   
  
  
  
Mass of PCL in Preparation (g) 0.5021 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5021 
 
Percentage Yield (%) 63.49   
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10kDa Without FLT (PVA 13 - 23kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.7225 14.8125 
2 14.6674 14.7664 
3 14.7514 14.8400 
4 14.7162 14.7643 
Total 58.8575 59.1832 
 
Dry Weight - Test Tube (g) 0.3257   
  
  
  
Mass of PCL in Preparation (g) 0.5010 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5010 
 
Percentage Yield (%) 65.01   
10kDa Without FLT (PVA 13 - 23kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6399 14.7180 
2 14.7554 14.8350 
3 14.6753 14.7904 
4 14.6911 14.7501 
Total  58.7617 59.0935 
    
Dry Weight - Test Tube (g) 0.3318   
  
  
  
Mass of PCL in Preparation (g) 0.5003 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5003 
  
Percentage Yield (%) 66.32   
Average Percentage Yield (%)           
(3 Sample)  
64.94 
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10kDa With FLT (PVA 30 - 70kDa) 
Sample 1 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6455 14.7305 
2 14.6487 14.7577 
3 14.6357 14.7243 
4 14.7114 14.7664 
Total 58.6413 58.9789 
 
Dry Weight - Test Tube (g) 0.3376   
  
  
  
Mass of PCL in Preparation (g) 0.5013 
Mass of FLT in Preparation (g) 0.0252 
Total (PCL +/- FLT) (g) 0.5265 
 
Percentage Yield (%) 64.12   
10kDa With FLT (PVA 30 - 70kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6821 14.7611 
2 14.7699 14.8602 
3 14.8116 14.8892 
4 14.6221 14.7224 
Total 58.8857 59.2329 
 
Dry Weight - Test Tube (g) 0.3472   
  
  
  
Mass of PCL in Preparation (g) 0.5028 
Mass of FLT in Preparation (g) 0.0249 
Total (PCL +/- FLT) (g) 0.5277 
 
Percentage Yield (%) 65.79   
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10kDa With FLT (PVA 30 - 70kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6324 14.7256 
2 14.7691 14.8642 
3 14.7366 14.8064 
4 14.7225 14.8045 
Total  58.8606 59.2007 
    
Dry Weight - Test Tube (g) 0.3401   
  
  
  
Mass of PCL in Preparation (g) 0.5016 
Mass of FLT in Preparation (g) 0.0255 
Total (PCL +/- FLT) (g) 0.5271 
  
Percentage Yield (%) 64.52   
Average Percentage Yield (%)           
(3 Sample)  
64.81 
10kDa Without FLT (PVA 30 - 70kDa) 
Sample 1 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6354 14.7149 
2 14.6954 14.7754 
3 14.6112 14.7060 
4 14.6475 14.7229 
Total 58.5895 58.9192 
 
Dry Weight - Test Tube (g) 0.3297   
  
  
  
Mass of PCL in Preparation (g) 0.5000 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5000 
 
Percentage Yield (%) 65.94   
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10kDa Without FLT (PVA 30 - 70kDa) 
Sample 2 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.7330 14.8095 
2 14.6008 14.6881 
3 14.7156 14.7761 
4 14.6481 14.7443 
Total 58.6975 59.0180 
 
Dry Weight - Test Tube (g) 0.3205   
  
  
  
Mass of PCL in Preparation (g) 0.5015 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5015 
 
Percentage Yield (%) 63.91   
10kDa Without FLT (PVA 30 - 70kDa) 
Sample 3 
Test 
Tube 
Empty Test Tube Weight (TT) (g) Total Dry Weight (DW) (g) 
 
1 14.6399 14.6973 
2 14.7554 14.8448 
3 14.6753 14.7510 
4 14.6911 14.7790 
Total  58.7617 59.0721 
    
Dry Weight - Test Tube (g) 0.3104   
  
  
  
Mass of PCL in Preparation (g) 0.5014 
Mass of FLT in Preparation (g) 0.0000 
Total (PCL +/- FLT) (g) 0.5014 
  
Percentage Yield (%) 61.91   
Average Percentage Yield (%)           
(3 Sample)  
63.92 
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Appendix : 3.5.1. 
Mastersizer PCL 80kDa : PVA 13-23kDa (-FLT) 
 
 
Sanjit S. Chaggar 1004138 Masters of Philosophy 
82 | P a g e  
 
Mastersizer PCL 80kDa : PVA 13-23kDa (+FLT) 
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Mastersizer PCL 80kDa : PVA 30-70kDa (-FLT) 
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Mastersizer PCL 80kDa : PVA 30-70kDa (+FLT) 
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Mastersizer PCL 65kDa : PVA 13-23kDa (-FLT) 
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Mastersizer PCL 65kDa : PVA 13-23kDa (+FLT) 
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Mastersizer PCL 65kDa : PVA 30-70kDa (-FLT) 
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Mastersizer PCL 65kDa : PVA 30-70kDa (+FLT) 
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Mastersizer PCL 10kDa : PVA 13-23kDa (-FLT) 
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Mastersizer PCL 10kDa : PVA 13-23kDa (+FLT) 
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Mastersizer PCL 10kDa : PVA 30-70kDa (-FLT) 
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Mastersizer PCL 10kDa : PVA 30-70kDa (+FLT) 
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Appendix : 3.6.1. 
 
Standard Calibration Curve of Flutamide Data 
 
 
Stock 
Solution 5mg 
in 100ml of 
Ethanol 
Absorbance 
at 300nm 
Sample 1 
 
Actual 
Concentration 
(mg/ml) 
Absorbance 
at 300nm 
Sample 2 
 
Actual 
Concentration 
(mg/ml) 
Absorbance 
at 300nm 
Sample 3 
15 0.003 0.000078125 0.002 0.000078125 0.007 
14 0.009 0.00015625 0.008 0.00015625 0.005 
13 0.064 0.00003125 0.068 0.00003125 0.065 
12 0.074 0.000625 0.073 0.000625 0.073 
11 0.087 0.00125 0.084 0.00125 0.081 
10 0.103 0.0025 0.103 0.0025 0.101 
9 0.211 0.005 0.215 0.005 0.218 
8 0.427 0.01 0.420 0.01 0.317 
7 0.504 0.015 0.605 0.015 0.635 
6 0.871 0.02 0.778 0.02 0.719 
5 0.915 0.025 0.926 0.025 0.985 
4 1.150 0.03 1.078 0.03 1.088 
3 1.330 0.035 1.276 0.035 1.337 
2 1.544 0.04 1.469 0.04 1.518 
1 1.725 0.045 1.704 0.045 1.718 
Stock  1.885 Stock  1.905 Stock  1.883 
 
Actual Conc (mg/ml) 
Average Absorbance at 
300nm of all 3 samples 
0.000078125 0.00400 
0.00015625 0.00733 
0.00003125 0.06567 
0.000625 0.07333 
0.00125 0.08400 
0.0025 0.10233 
0.005 0.21467 
0.01 0.38800 
0.015 0.58133 
0.02 0.78933 
0.025 0.94200 
0.03 1.10533 
0.035 1.31433 
0.04 1.51033 
0.045 1.71567 
0.05 1.89400 
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Appendix : 3.6.2. 
In-vitro Percentage Drug Release (PDR) 
calculations 
 
First calculate the theoretical 100% of FLT present in the 40mg (0.040g) sample used within the 
dissolution test: 
 
The original sample yielded 400mg (0.4000g) PCL+FLT. Therefore: 
(0.0400g/0.4000g)*100 = 10.00% (20mg) of the PCL+FLT sample was used in the dissolution test. 
 
Using this we can find out the theoretical 100% of FLT that was present in the 20mg sample used 
within the dissolution test: 
(0.0500g/100)*10.00% = 5.000mg (0.005000g) 
 
This therefore shows that in the 20mg sample 8.000mg of FLT was encapsulated. 
We can therefore calculate the concentration of the encapsulated FLT as: 
5.000mg/900mL = 0.00555mg/mL 
 
Using the equation of the line from the standard curve we can calculate the concentration of FLT 
released at each time point: 
e.g.: y=37.879x x – Concentration (mg/mL) 
 y – Absorbance (300nm) 
 
Therefore to find our concentration we use: 
x = y/37.879 (all results as seen on the excel document). 
Once the concentrations have been calculated we can calculate the Percentage Drug Released (PDR) 
as follows:  
PDR = (concentration from time point obtained/initial concentration)*100 
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Appendix : 3.6.3. 
 
Release Study Raw Data  
 
PCL 80kDa/ PVA 13-23kDa 
Hours Absorbance (300nm) Average Absorbance (300nm) Standard Deviation (+/-) 
0 
0 
0 0 0 
0 
 
0.5 
0.02 
0.016333333 0.005507571 0.01 
0.019 
 
1 
0.009 
0.008666667 0.001527525 0.01 
0.007 
 
2 
0.009 
0.008333333 0.00305505 0.011 
0.005 
 
4 
0.007 
0.007333333 0.00057735 0.007 
0.008 
 
8 
0.018 
0.017666667 0.003511885 0.014 
0.021 
 
24 
0.014 
0.017 0.002645751 0.018 
0.019 
 
48 
0.022 
0.018666667 0.004932883 0.021 
0.013 
 
72 
0.013 
0.011 0.002645751 0.012 
0.008 
 
96 
0.012 
0.010333333 0.001527525 0.01 
0.009 
 
168 0.013 0.010666667 0.002516611 
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0.011 
0.008 
 
216 
0.008 
0.010333333 0.00321455 0.014 
0.009 
 
264 
0.006 
0.008333333 0.002516611 0.011 
0.008 
 
336 
0.006 
0.006333333 0.001527525 0.008 
0.005 
 
384 
0 
0.000666667 0.001154701 0.002 
0 
 
432 
0 
0 0 0 
0 
 
PCL 80kDa/ PVA 30-70kDa 
Hours Absorbance (300nm) Average Absorbance (300nm) Standard Deviation (+/-) 
0 
0 
0 0 0 
0 
 
0.5 
0 
0 0 0 
0 
 
1 
0.01 
0.012333333 0.002081666 0.013 
0.014 
 
2 
0.006 
0.009666667 0.00321455 0.012 
0.011 
 
4 
0.008 
0.010333333 0.00321455 0.014 
0.009 
 
8 
0.012 
0.011 0.001 0.011 
0.01 
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24 
0.016 
0.014333333 0.001527525 0.014 
0.013 
 
48 
0.02 
0.022 0.002645751 0.025 
0.021 
 
72 
0.022 
0.019333333 0.002516611 0.019 
0.017 
 
96 
0.011 
0.012333333 0.006110101 0.019 
0.007 
 
168 
0.013 
0.009666667 0.002886751 0.008 
0.008 
 
216 
0.019 
0.019333333 0.00057735 0.019 
0.02 
 
264 
0.011 
0.014 0.002645751 0.015 
0.016 
 
336 
0.009 
0.009333333 0.001527525 0.011 
0.008 
 
384 
0.005 
0.005 0.003 0.008 
0.002 
 
432 
0 
0 0 0 
0 
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PCL 65kDa/ PVA 13-23kDa 
Hours Absorbance (300nm) Average Absorbance (300nm) Standard Deviation (+/-) 
0 
0 
0 0 0 
0 
 
0.5 
0.019 
0.016333333 0.00305505 0.013 
0.017 
 
1 
0.011 
0.005333333 0.005131601 0.004 
0.001 
 
2 
0.01 
0.009666667 0.00057735 0.009 
0.01 
 
4 
0.012 
0.012333333 0.001527525 0.011 
0.014 
 
8 
0.017 
0.017 0.002 0.015 
0.019 
 
24 
0.018 
0.016666667 0.001527525 0.015 
0.017 
 
48 
0.014 
0.013 0.001 0.013 
0.012 
 
72 
0.01 
0.009666667 0.00057735 0.01 
0.009 
 
96 
0.016 
0.013 0.002645751 0.012 
0.011 
 
168 
0.009 
0.008666667 0.001527525 0.01 
0.007 
 
216 
0.004 
0.002666667 0.001527525 0.001 
0.003 
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264 
0.002 
0.001666667 0.00057735 0.002 
0.001 
 
336 
0 
0 0 0 
0 
 
384 
0 
0 0 0 
0 
 
432 
0 
0 0 0 
0 
 
 
PCL 65kDa/ PVA 30-70kDa 
Hours Absorbance (300nm) Average Absorbance (300nm) Standard Deviation (+/-) 
0 
0 
0 0 0 
0 
 
0.5 
0 
0 0 0 
0 
 
1 
0.006 
0.007333333 0.001527525 0.007 
0.009 
 
2 
0.007 
0.009333333 0.002081666 0.011 
0.01 
 
4 
0.007 
0.008333333 0.00321455 0.006 
0.012 
 
8 
0.011 
0.011 0.003 0.008 
0.014 
 
24 
0.019 
0.019333333 0.001527525 0.018 
0.021 
 
48 
0.02 
0.020333333 0.00057735 
0.02 
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0.021 
 
72 
0.011 
0.014 0.003605551 0.018 
0.013 
 
96 
0.01 
0.011666667 0.002081666 0.014 
0.011 
 
168 
0.009 
0.010666667 0.003785939 0.015 
0.008 
 
216 
0.006 
0.01 0.003464102 0.012 
0.012 
 
264 
0.004 
0.006333333 0.002081666 0.007 
0.008 
 
336 
0.004 
0.005 0.001 0.006 
0.005 
 
384 
0 
0 0 0 
0 
 
432 
0 
0 0 0 
0 
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PCL 10kDa/ PVA 13-23kDa 
Hours Absorbance (300nm) Average Absorbance (300nm) Standard Deviation (+/-) 
0 
0 
0 0 0 
0 
 
0.5 
0.007 
 
0.007333333 
 
0.001527525 
0.006 
0.009 
 
1 
0.009 
0.008666667 0.001527525 0.007 
0.01 
 
2 
0.01 
0.009666667 0.001527525 0.011 
0.008 
 
4 
0.008 
0.007 0.001732051 0.005 
0.008 
 
8 
0.006 
0.008 0.002 0.008 
0.01 
 
24 
0.011 
0.009666667 0.001527525 0.01 
0.008 
 
48 
0.006 
0.007 0.001 0.007 
0.008 
 
72 
0.005 
0.006333333 0.001527525 0.008 
0.006 
 
96 
0.002 
0.002 0.001 0.003 
0.001 
 
168 
0 
0 0 0 
0 
 
216 
0 
0 0 0 
0 
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264 
0 
0 0 0 
0 
 
336 
0 
0 0 0 
0 
 
384 
0 
0 
0 
 
0 
0 
 
432 
0 
0 0 0 
0 
 
 
PCL 10kDa/ PVA 30-70kDa 
Hours Absorbance (300nm) Average Absorbance (300nm) Standard Deviation (+/-) 
0 
0 
0 0 0 
0 
 
0.5 
0.005 
0.004333333 0.004041452 0 
0.008 
 
1 
0.006 
0.008 0.002645751 0.011 
0.007 
 
2 
0.003 
0.006666667 0.003511885 0.007 
0.01 
 
4 
0.008 
0.009 0.001732051 0.008 
0.011 
 
8 
0.012 
0.012 0.001 0.013 
0.011 
 
24 
0.012 
0.011666667 0.002516611 0.014 
0.009 
 
48 0.009 0.007 0.003464102 
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0.003 
0.009 
 
72 
0.006 
0.003666667 0.00321455 0.005 
0 
 
96 
0.006 
0.003666667 0.002516611 0.004 
0.001 
 
168 
0.001 
0.003 0.002 0.003 
0.005 
 
216 
0 
0 0 0 
0 
 
264 
0 
0 0 0 
0 
 
336 
0 
0 0 0 
0 
 
384 
0 
0 0 0 
0 
 
432 
0 
0 0 0 
0 
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Appendix : 3.6.4.  
 
Drug Release Profile Calculation Table 
 
PCL 80kDa/ PVA 13-23kDa 
Hours  
Average 
Absorbance  
Cumulative 
Absorbance  
x=y/37.879 - Concentration 
(mg/ml)  
Percentage 
Drug Release 
(%) 
Standard 
Deviation  
Standard Dev 
(Concentration) 
Standard Dev 
(Percentage) 
0 0 0 0 0 0 0 0 
0.5 0.016333333 0.016333333 0.000431198 7.769325861 0.005507571 0.000145399 2.619802671 
1 0.008666667 0.025 0.000659996 11.8918253 0.001527525 4.03264E-05 0.726602528 
2 0.008333333 0.033333333 0.000879995 15.85576706 0.00305505 8.06529E-05 1.453205055 
4 0.007333333 0.040666667 0.001073594 19.34403582 0.00057735 1.5242E-05 0.274629941 
8 0.017666667 0.058333333 0.001539991 27.74759236 0.003511885 9.27132E-05 1.670508718 
24 0.017 0.075333333 0.001988789 35.83403356 0.002645751 6.98474E-05 1.258512495 
48 0.018666667 0.094 0.002481586 44.71326312 0.004932883 0.000130227 2.346439249 
72 0.011 0.105 0.002771984 49.94566625 0.002645751 6.98474E-05 1.258512495 
96 0.010333333 0.115333333 0.003044783 54.86095404 0.001527525 4.03264E-05 0.726602528 
168 0.010666667 0.126 0.003326381 59.9347995 0.002516611 6.64382E-05 1.197084162 
216 0.010333333 0.136333333 0.00359918 64.85008729 0.00321455 8.48637E-05 1.529074801 
264 0.008333333 0.144666667 0.003819179 68.81402906 0.002516611 6.64382E-05 1.197084162 
336 0.006333333 0.151 0.003986378 71.8266248 0.001527525 4.03264E-05 0.726602528 
384 0.000666667 0.151666667 0.004003978 72.14374014 0.001154701 3.04839E-05 0.549259883 
432 0 0.151666667 0.004003978 72.14374014 0 0 0 
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PCL 80kDa/ PVA 30-70kDa 
Hours  
Average 
Absorbance  
Cumulative 
Absorbance  
x=y/37.879 - Concentration 
(mg/ml)  
Percentage 
Drug Release 
(%) 
Standard 
Deviation  
Standard Dev 
(Concentration) 
Standard Dev 
(Percentage) 
0 0 0 0 0 0 0 0 
0.5 0 0 0 0 0 0 0 
1 0.012333333 0.012333333 0.000325598 5.866633814 0.002081666 5.49557E-05 0.990192336 
2 0.009666667 0.022 0.000580797 10.46480626 0.00321455 8.48637E-05 1.529074801 
4 0.010333333 0.032333333 0.000853595 15.38009405 0.00321455 8.48637E-05 1.529074801 
8 0.011 0.043333333 0.001143994 20.61249718 0.001 2.63999E-05 0.475673012 
24 0.014333333 0.057666667 0.001522391 27.43047702 0.001527525 4.03264E-05 0.726602528 
48 0.022 0.079666667 0.002103188 37.89528328 0.002645751 6.98474E-05 1.258512495 
72 0.019333333 0.099 0.002613585 47.09162818 0.002516611 6.64382E-05 1.197084162 
96 0.012333333 0.111333333 0.002939184 52.95826199 0.006110101 0.000161306 2.906410111 
168 0.009666667 0.121 0.003194382 57.55643444 0.002886751 7.62098E-05 1.373149707 
216 0.019333333 0.140333333 0.003704779 66.75277934 0.00057735 1.5242E-05 0.274629941 
264 0.014 0.154333333 0.004074377 73.4122015 0.002645751 6.98474E-05 1.258512495 
336 0.009333333 0.163666667 0.004320776 77.85181628 0.001527525 4.03264E-05 0.726602528 
384 0.005 0.168666667 0.004452775 80.23018134 0.003 7.91996E-05 1.427019036 
432 0 0.168666667 0.004452775 80.23018134 0 0 0 
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PCL 65kDa/ PVA 13-23kDa 
Hours  
Average 
Absorbance  
Cumulative 
Absorbance  
x=y/37.879 - Concentration 
(mg/ml)  
Percentage 
Drug Release 
(%) 
Standard 
Deviation  
Standard Dev 
(Concentration) 
Standard Dev 
(Percentage) 
0 0 0 0 0 0 0 0 
0.5 0.016333333 0.016333333 0.000431198 7.769325861 0.00305505 8.06529E-05 1.453205055 
1 0.005333333 0.021666667 0.000571997 10.30624859 0.005131601 0.000135474 2.440964313 
2 0.009666667 0.031333333 0.000827195 14.90442104 0.00057735 1.5242E-05 0.274629941 
4 0.012333333 0.043666667 0.001152794 20.77105485 0.001527525 4.03264E-05 0.726602528 
8 0.017 0.060666667 0.001601591 28.85749606 0.002 5.27997E-05 0.951346024 
24 0.016666667 0.077333333 0.002041589 36.78537959 0.001527525 4.03264E-05 0.726602528 
48 0.013 0.090333333 0.002384787 42.96912874 0.001 2.63999E-05 0.475673012 
72 0.009666667 0.1 0.002639985 47.56730119 0.00057735 1.5242E-05 0.274629941 
96 0.013 0.113 0.002983183 53.75105035 0.002645751 6.98474E-05 1.258512495 
168 0.008666667 0.121666667 0.003211982 57.87354978 0.001527525 4.03264E-05 0.726602528 
216 0.002666667 0.124333333 0.003282382 59.14201115 0.001527525 4.03264E-05 0.726602528 
264 0.001666667 0.126 0.003326381 59.9347995 0.00057735 1.5242E-05 0.274629941 
336 0 0.126 0.003326381 59.9347995 0 0 0 
384 0 0.126 0.003326381 59.9347995 0 0 0 
432 0 0.126 0.003326381 59.9347995 0 0 0 
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PCL 65kDa/ PVA 30-70kDa 
Hours  
Average 
Absorbance  
Cumulative 
Absorbance  
x=y/37.879 - Concentration 
(mg/ml)  
Percentage 
Drug Release 
(%) 
Standard 
Deviation  
Standard Dev 
(Concentration) 
Standard Dev 
(Percentage) 
0 0 0 0 0 0 0 0 
0.5 0 0 0 0 0 0 0 
1 0.007333333 0.007333333 0.000193599 3.488268754 0.001527525 4.03264E-05 0.726602528 
2 0.009333333 0.016666667 0.000439998 7.927883532 0.002081666 5.49557E-05 0.990192336 
4 0.008333333 0.025 0.000659996 11.8918253 0.00321455 8.48637E-05 1.529074801 
8 0.011 0.036 0.000950395 17.12422843 0.003 7.91996E-05 1.427019036 
24 0.019333333 0.055333333 0.001460792 26.32057333 0.001527525 4.03264E-05 0.726602528 
48 0.020333333 0.075666667 0.001997589 35.99259123 0.00057735 1.5242E-05 0.274629941 
72 0.014 0.089666667 0.002367187 42.6520134 0.003605551 9.5186E-05 1.715063435 
96 0.011666667 0.101333333 0.002675185 48.20153187 0.002081666 5.49557E-05 0.990192336 
168 0.010666667 0.112 0.002956783 53.27537733 0.003785939 9.99482E-05 1.800868958 
216 0.01 0.122 0.003220782 58.03210745 0.003464102 9.14518E-05 1.647779649 
264 0.006333333 0.128333333 0.003387981 61.04470319 0.002081666 5.49557E-05 0.990192336 
336 0.005 0.133333333 0.00351998 63.42306825 0.001 2.63999E-05 0.475673012 
384 0 0.133333333 0.00351998 63.42306825 0 0 0 
432 0 0.133333333 0.00351998 63.42306825 0 0 0 
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PCL 10kDa/ PVA 13-23kDa 
Hours  
Average 
Absorbance  
Cumulative 
Absorbance  
x=y/37.879 - Concentration 
(mg/ml)  
Percentage 
Drug Release 
(%) 
Standard 
Deviation  
Standard Dev 
(Concentration) 
Standard Dev 
(Percentage) 
0 0 0 0 0 0 0 0 
0.5 0.007333333 0.007333333 0.000193599 3.488268754 0.001527525 4.03264E-05 0.726602528 
1 0.008666667 0.016 0.000422398 7.610768191 0.001527525 4.03264E-05 0.726602528 
2 0.009666667 0.025666667 0.000677596 12.20894064 0.001527525 4.03264E-05 0.726602528 
4 0.007 0.032666667 0.000862395 15.53865172 0.001732051 4.57259E-05 0.823889824 
8 0.008 0.040666667 0.001073594 19.34403582 0.002 5.27997E-05 0.951346024 
24 0.009666667 0.050333333 0.001328793 23.94220827 0.001527525 4.03264E-05 0.726602528 
48 0.007 0.057333333 0.001513592 27.27191935 0.001 2.63999E-05 0.475673012 
72 0.006333333 0.063666667 0.001680791 30.28451509 0.001527525 4.03264E-05 0.726602528 
96 0.002 0.065666667 0.00173359 31.23586112 0.001 2.63999E-05 0.475673012 
168 0 0.065666667 0.00173359 31.23586112 0 0 0 
216 0 0.065666667 0.00173359 31.23586112 0 0 0 
264 0 0.065666667 0.00173359 31.23586112 0 0 0 
336 0 0.065666667 0.00173359 31.23586112 0 0 0 
384 0 0.065666667 0.00173359 31.23586112 0 0 0 
432 0 0.065666667 0.00173359 31.23586112 0 0 0 
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PCL 10kDa/ PVA 30-70kDa 
Hours  
Average 
Absorbance  
Cumulative 
Absorbance  
x=y/37.879 - Concentration 
(mg/ml)  
Percentage 
Drug Release 
(%) 
Standard 
Deviation  
Standard Dev 
(Concentration) 
Standard Dev 
(Percentage) 
0 0 0 0 0 0 0 0 
0.5 0.004333333 0.004333333 0.000114399 2.061249718 0.004041452 0.000106694 1.92240959 
1 0.008 0.012333333 0.000325598 5.866633814 0.002645751 6.98474E-05 1.258512495 
2 0.006666667 0.019 0.000501597 9.037787226 0.003511885 9.27132E-05 1.670508718 
4 0.009 0.028 0.000739196 13.31884433 0.001732051 4.57259E-05 0.823889824 
8 0.012 0.04 0.001055994 19.02692048 0.001 2.63999E-05 0.475673012 
24 0.011666667 0.051666667 0.001363992 24.57643895 0.002516611 6.64382E-05 1.197084162 
48 0.007 0.058666667 0.001548791 27.90615003 0.003464102 9.14518E-05 1.647779649 
72 0.003666667 0.062333333 0.001645591 29.65028441 0.00321455 8.48637E-05 1.529074801 
96 0.003666667 0.066 0.00174239 31.39441879 0.002516611 6.64382E-05 1.197084162 
168 0.003 0.069 0.00182159 32.82143782 0.002 5.27997E-05 0.951346024 
216 0 0.069 0.00182159 32.82143782 0 0 0 
264 0 0.069 0.00182159 32.82143782 0 0 0 
336 0 0.069 0.00182159 32.82143782 0 0 0 
384 0 0.069 0.00182159 32.82143782 0 0 0 
432 0 0.069 0.00182159 32.82143782 0 0 0 
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Appendix : 5.2.1. 
 
Task Name:    Cytotoxicity Test 
Date:  
Location: Cell Culture Research Lab (Keith HoldingK.Holding@wlv.ac.uk Ext 2655 and Dr. Angie Williams 
A.S.Williams@wlv.ac.uk Ext 2128) 
1. Chemicals 
 
 Cancer cell lines 
 Eagle's Minimal Essential Medium + 2mM Glutamine + 1% Non-Essential Amino 
Acids + 10% Foetal Bovine Serum. (DMEM) 
 Phosphate-Buffered Saline (PBS) 
 (Trypsin)-EDTA solution 
 Thiazolyl Blue Tetrazolium Bromide (MTT) 
 Dimethyl Sulfoxide(DMSO) 
 Sorensen’s buffer (Sodium Chloride + Glycine) 
 
2. Glassware, facilities and instruments 
 
 Microtitre plate reader (540 nm) 
 96-well Microtitre plate (flat-bottomed) 
 Inverted microscope 
 Multi-channel pipette 
 CO2 controlled incubator 
 Laminar flow hood 
 Sterile tubes (5 mL) 
 Pasteur pipettes  
 Sterile pipette tips 
 Conical centrifuge tube 
 Centrifuge – 1500 x g 
 T75 Culture flask (Filtered cap)  
 Haemocytometer 
 Haemocytometer cover slip 
 Magnetic Stirrer 
 Hot Plate 
 0.45 μm Plastic vacuum filter (Vol. 500 mL)  
 Foil 
 750 mL beaker 
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 Waste Container 
3. Protocol 
 
Experimental Day 1 
 
Sub-culturing 
 
1. Visually check the tissue culture medium for contamination or cellular deterioration.  
(See Note 1) 
 
2. Examine adherent cells for 70-80% confluence using an inverted light microscope.   
3. Aspirate the spent media using a sterile Pasteur pipette from the culture flask into a 
waste container. 
4. Measure out 5ml of Phosphate-Buffered Saline (PBS). 
5. Wash adherent cells in 5ml of PBS. 
6. Aspirate the solution using a sterile pipette into a waste container. 
7. Measure out 2.0 to 3.0 mL of Trypsin-EDTA solution. 
8. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to culture flask.     
9. Incubate the culture flask for 2-3 minutes at 37°C.  
10. Observe cells under an inverted microscope until cell layer is detached.  
11. Measure out 3.0 to 5.0mL of Dulbecco’s Modified Eagle medium (DMEM). 
12. Add 3 to 5 ml of DMEM into the culture flask.  
13. Transfer the cell suspension into a conical centrifuge tube.  
14. Place the conical centrifuge tube into a centrifuge and spin cells at 1300-1500 rpm 
for 5 minutes. 
15. Aspirate the supernatant into a waste container, leaving the pellet. 
16. Measure out 8 to 10mL of DMEM depending on the size of the pellet.  
17. Re-suspend the pellet in 6-8 mL of DMEM into the culture flask.   
18. Gently pipette to ensure a homogenous solution of single cells. 
19. Pipette 10μL of the cell suspension onto a haemocytometer with haemocytometer 
cover slip (it is a special cover slip you can get from sigma)  and examine the cells 
under the inverted light microscope to see if the cells are present.(See Note 2) 
 
20. Count the cells using a counter – 1 cell is equal to 10,000 cells/mL of the suspension 
you have.  
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21. Calculate how many wells you have and how much cells you need per well.  
 
 Example: You have 3 plates with 60 working wells in each (leaving outside wells 
for water) the total no of wells is 180.  
 180 wells x 200 μl = 36,000 μl = 36 mL. So you can prepare 40 mL. 
 At the same time if you need 5,000 cells in each well / 200μl. 
 Therefore; 1 mL/25,000 cells. 
 10 mL/ 250,000 cells or 0.25x106 cells. 
 For 40 mL it will be 1x106 cells. 
 
 If you have 0.5x106 cells/ mL in your actual cell suspension after counting. 
 Add 2mL of Cells + 38 mL of fresh DMEM to make 1x106 cells/40 ml. 
 In other words 5,000 cells/ 200 μL 
 
 Mix cells and media well to make uniform suspension for accuracy. 
 
22. Use a petri dish or multichannel pipette dish and pour your calculated cell 
suspension and aliquot 200 μL in each well using a multi-channel pipette. For 
accuracy frequent mixing in between is essential. 
23. Incubate the 96 well plates for 24 h at 37°C, 5% CO2 (CO2 controlled incubator). 
 
Experimental Day 2 
 
1. Aspirate off the media without disturbing the layer of cells using a Pasteur pipette.  
 
2. Calculate the concentration of the initial test drug for 1:2 serial dilutions.  
 
 Example: Temozolomide (TmZ) needed at an initial concentration of 500 μM in 
8ml PBS solution.   
 
 8 mL = 8000 μL 
 100 mM Stock TmZ = 100,000 μM Stock TmZ 
 
 8000 μL x 500 μM  
 
 
 Therefore;  40 μL TmZ + 7,960 40 μL PBS = 8000 μL ( TmZ 500 μM in 8ml PBS 
solution) 
 
3. Using 8 test tubes pour your calculated measure of the test drug and PBS into the 
first test tube to make an 8mL solution (Test tube 1).  
 
4. Measure out 30mL of PBS into a beaker using a pipette. 
 
5. Aliquot 4mL of PBS into each of the 7 remaining test tubes (Test Tubes 2 - 8). 
100,000 μM 
= 40 μL TmZ 
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6. Transfer 4 mL of Test Tube 1 solution into Test tube 2 using a pipette. 
 
7. Repeat this procedure transferring 4 mL of solution from test tubes 2 to 3, 3 to 4, 4 
to 5, 5 to 6, 6 to 7 and 7 to 8. (High to Low Concentration).    
 
8. Aliquot 200 μL of each dilution into the allocated wells in the three plates. 
 
9. Incubate the plate for an appropriate length of time at 37°C (5% CO2) subject to the 
drug used. 
   
Experimental Day 3 
 
1) Pippette 20 μL of MTT solution into each well of the cell plate.  
 
2) Place 96-well plate lid over the plate and wrap with foil, then incubate (37°C, 5% 
CO2) for 4 hours.  (See Note 3) 
 
3) Aspirate the media from the wells. 
 
4) Pipette 80 μL of Dimethyl Sulfoxide (DMSO)into each well. 
 
5) Pipette 20 μL of Sorensen’s buffer into each well. 
 
6) Read on a multi-well plate reader at 540 nm.  
 
4. Preparations 
 
MTT Stock Solution 
 
1) Weigh out 2.5g of MTT stock. 
 
2) Measure out 500 mL PBS in 750 mL beaker. 
 
3) Dissolve MTT stock in PBS under gentle stirring (6-8 hrs) and wrap the beaker with 
foil. 
 
4) Filter the MTT solution using a 0.45 μm Plastic vacuum filter (Vol. 500 mL) and wrap 
with foil (Store at 2-4oC).(See Note 3) 
 
Sorensen’s Buffer 
 
1) Weigh out 2.9g of Sodium Chloride. 
 
2) Weigh out 3.8g of Glycine. 
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3) Dissolve the Sodium Chloride and Glycine together in 500 mL distilled water. 
 
 
5. Notes to highlight 
 
Note1: Check for cell medium contamination – DMEM solution will turn from pink/ red to 
orange   showing a change in pH due to CO2 absorption.  
 
Note 2: Check for clumping of cells - if any clumps are present re-suspend and follow 
procedure from step 14. 
 
Note 3: Cover MTT solution with foil as it is light sensitive to prevent photo degradation. 
Solution must be stored at 2-4°C in the dark (Up to 18months). 
 
4. Precautions 
 
MTT is toxic and may cause heritable genetic defects. In case of contact, immediately flush 
eyes or skin with copious amounts of water. If swallowed, wash out mouth with water 
provided person is conscious. Call a physician. 
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